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The reporting characteristics of bovine respiratory disease clinical
intervention trials published prior to and following publication of the
REFLECT statement
Abstract
The goal of the REFLECT Statement (Reporting guidElines For randomized controLled trials in livEstoCk
and food safeTy) (published in 2010) was to provide the veterinary research community with reporting
guidelines tailored for randomized controlled trials for livestock and food safety. Our objective was to
determine the prevalence of REFLECT Statement reporting of items 1 to 19 in controlled trials published in
journals between 1970 and 2017 examining the comparative efficacy of FDA-registered antimicrobials against
naturally acquired BRD (bovine respiratory disease) in weaned beef calves in Canada or the USA, and to
compare the prevalence of reporting before and after 2010, when REFLECT was published. We divided
REFLECT Statement, items 3, 5, 10, and 11 into subitems, because each dealt with multiple elements
requiring separate assessment. As a result, 28 different items or subitems were evaluated independently. We
searched MEDLINE® and CABI (CAB Abstracts® and Global Health®) (Web of ScienceTM) in April 2017
and screened 2327 references. Two reviewers independently assessed the reporting of each item and subitem.
Ninety-five references were eligible for the study. The reporting of the REFLECT items showed a point
estimate for the prevalence ratio > 1 (i.e. a higher proportion of studies published post-2010 reported this
item compared to studies published pre-2010), apart from items 10.3, i.e., item 10, subitem 3 (who assigned
study units to the interventions), 13 (the flow of study units through the study), 16 (number of study units in
analysis), 18 (multiplicity), and 19 (adverse effects). Fifty-three (79%) of 67 studies published before 2010
and all 28 (100%) papers published after 2010 reported using a random allocation method in either the title,
abstract, or methods (Prevalence ratio = 1.25; 95% CI (1.09,1.43)). However, 8 studies published prior to
2010 and 7 studies published post-2010 reported the term "systematic randomization" or variations of this
term (which is not true randomization) to describe the allocation procedure. Fifty-five percent (37/67) of
studies published pre-2010 reported blinding status (blinded/not blinded) of outcome assessors, compared
to 24/28 (86%) of studies published post-2010 (Prevalence ratio =1.5, 95% CI (1.19, 2.02)). The reporting of
recommended items in journal articles in this body of work is generally improving; however, there is also
evidence of confusion about what constitutes a random allocation procedure, and this suggests an educational
need. As this study is observational, this precludes concluding that the publication of the REFLECT
Statement was the cause of this trend.
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Abstract 
The goal of the REFLECT Statement (Reporting guidElines For randomized controLled trials in 
livEstoCk and food safeTy) (published in 2010) was to provide the veterinary research 
community with reporting guidelines tailored for randomized controlled trials for livestock and 
food safety. Our objective was to determine the prevalence of REFLECT Statement reporting of 
items 1 to 19 in controlled trials published in journals between 1970 and 2017 examining the 
comparative efficacy of FDA-registered antimicrobials against naturally acquired BRD (bovine 
respiratory disease) in weaned beef calves in Canada or the USA, and to compare the prevalence 
of reporting before and after 2010, when REFLECT was published. We divided REFLECT 
Statement, items 3, 5, 10, and 11 into subitems, because each dealt with multiple elements 
requiring separate assessment. As a result, 28 different items or subitems were evaluated 
independently. We searched MEDLINE® and CABI (CAB Abstracts® and Global Health®) 
(Web of ScienceTM) in April 2017 and screened 2327 references. Two reviewers independently 
assessed the reporting of each item and subitem. Ninety-five references were eligible for the 
study. The reporting of the REFLECT items showed a point estimate for the prevalence ratio > 1 
(i.e. a higher proportion of studies published post-2010 reported this item compared to studies 
published pre-2010), apart from items 10.3, i.e., item 10, subitem 3 (who assigned study units to 
the interventions), 13 (the flow of study units through the study), 16 (number of study units in 
analysis), 18 (multiplicity), and 19 (adverse effects). Fifty-three (79%) of 67 studies published 
before 2010 and all 28 (100%) papers published after 2010 reported using a random allocation 
method in either the title, abstract, or methods (Prevalence ratio = 1.25; 95% CI (1.09,1.43)). 
However, 8 studies published prior to 2010 and 7 studies published post-2010 reported the term 
"systematic randomization" or variations of this term (which is not true randomization) to 
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describe the allocation procedure. Fifty-five percent (37/67) of studies published pre-2010 
reported blinding status (blinded/not blinded) of outcome assessors, compared to 24/28 (86%) of 
studies published post-2010 (Prevalence ratio =1.5, 95% CI (1.19, 2.02)). The reporting of 
recommended items in journal articles in this body of work is generally improving; however, 
there is also evidence of confusion about what constitutes a random allocation procedure, and 
this suggests an educational need. As this study is observational, this precludes concluding that 
the publication of the REFLECT Statement was the cause of this trend. 
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1.  Introduction 
1.1. Rationale 
In science, including veterinary science, there has been a movement toward improving 
the reporting of research protocols, conduct, and results (Altman et al., 2008; Begley, 2013; 
Groves and Godlee, 2012; Keiding, 2010; Simera et al., 2010; Simera and Altman, 2009; Sweet, 
2014). The rationale for these efforts is to enable the maximum value to be extracted from 
research results. Randomized controlled trials (RCTs) that are clearly reported allow the clinician 
to properly assess the efficacy of tested interventions and incorporate that information into 
making the best therapeutic and preventive decisions for patients. To improve the reporting of 
RCTs in human health, the CONSORT Statement (Consolidated Standards of Reporting Trials) 
was originally developed in 1996 and has been subsequently revised, with the latest version 
being published in 2010 (Moher et al., 2010; Schulz et al., 2010). The goal of reporting 
guidelines is to provide authors, reviewers, and editors with a list of items that should be 
included in a publication to encourage comprehensive reporting.  
In 2010, the REFLECT Statement (Reporting guidElines For randomized controLled 
trials in livEstoCk and food safeTy) was also published. The goal of the REFLECT Statement 
was to provide the veterinary research community with a reporting guideline tailored for 
randomized controlled trials conducted in the fields of livestock and food safety (O'Connor et al., 
2010b; Sargeant et al., 2010b). The rationale for a livestock-specific reporting guideline was that, 
although it is feasible to use the CONSORT Statement for RCTs in animals, authors, reviewers 
and editors might find the reporting guideline easier to adopt if the examples and terminology 
used were more consistent with livestock production; additionally, there are some features of 
livestock trials (such as complex organizational levels (e.g., pens, feedlots), different categories 
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of participants (i.e., owners/managers and animals), etc.) that CONSORT does not address. In 
2010, the REFLECT Statement was published in 5 journals, and several presentations were made 
to publicize the goal of the work (O'Connor et al., 2010a; O'Connor et al., 2010b; O'Connor et 
al., 2010c; O'Connor et al., 2010d; O'Connor et al., 2010e; Sargeant et al., 2010a; Sargeant et al., 
2010b). Further, a website devoted to the REFLECT Statement was developed and maintained 
(www.reflect-statement.org). One of the motivators for the REFLECT Statement was empirical 
evidence of poor reporting in livestock trials (Brace et al., 2010; O'Connor et al., 2010f; Sargeant 
et al., 2009; Wellman and O'Connor, 2007). Given the goal of reporting guidelines to improve 
comprehensive reporting, it is of interest to assess if such approaches have made an impact.   
1.2. Objectives 
Therefore, one objective of this study was to determine the prevalence of reporting of 
REFLECT items 1 to 19, with respect to clinical trials conducted in Canada and/or the USA 
examining the comparative efficacy of FDA-registered antimicrobials against naturally acquired 
BRD (bovine respiratory disease) in weaned beef calves, published in journals between 1970 and 
2017. The rationale for assessing this area was that a large number of RCTs were conducted, and 
we had previously evaluated the reporting of these studies and discussed the need for 
improvement (O'Connor et al., 2010f). Although we evaluated the first 19 items of the 
REFLECT Statement for the current study, items 3, 5, 10, and 11 had to be split into subitems, 
because each of these dealt with multiple elements that needed to be assessed separately. As a 
result, a total of 28 different items and subitems were evaluated independently. Further, although 
not an item on the REFLECT checklist (which assumes the study uses a random allocation 
method) it is clearly of broad interest to know if more authors are describing their allocation 
method. Therefore, another objective was to describe the number of studies pre- and post-2010 
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reporting any type of allocation method. This latter objective was not intended as an assessment 
of the validity of the allocation approach, i.e. not a risk-of-bias assessment; rather, the objective 
was only concerned with whether the authors described the method of allocation. 
2.  Methods 
2.1. Study population  
The current study was an observational survey. The population of interest was published 
controlled trials on naturally occurring bovine respiratory disease in weaned beef calves in 
Canadian and/or US feedlots. The interventions of interest were FDA-registered antimicrobials, 
and the outcome of interest was naturally occurring BRD (i.e., challenge trials were not relevant 
to this study). The study design of interest was controlled clinical trials. Our focus was further 
limited to journal publications, rather than technical reports or research reports, because efforts 
to improve reporting have mainly focused on journals.  
2.2. Study selection 
The literature search comprised three concepts to capture studies of interest: population, 
outcome, and intervention (search strings 1, 2, and 3, respectively, in Table 1) and was 
conducted on 15 April 2017 in MEDLINE® (Web of ScienceTM) (Table 1) and CABI (CAB 
Abstracts® and Global Health®) (Web of ScienceTM)(Supplementary Material 1). Search dates 
were restricted to 1970 to 2017, with no language or document-type restrictions. All search 
results were exported to DistillerSR® (Ottawa, ON, Canada), where they were de-duplicated. 
Additionally, the reference lists of relevant reviews captured by the original search were hand-
searched for potentially relevant references. Two additional relevant publications were found via 
a Google search while searching for PDF copies of previously identified studies. These two 
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articles were published in The Professional Animal Scientist journal; therefore, the index of this 
journal was also searched. 
Two reviewers screened each record for relevance in DistillerSR®. Eligible citations 
were manuscripts that described:  
1) Primary research published in journals,  
2) A study population of cattle housed in feedlots in Canada or the USA, 
3) At least one treatment arm with a product registered with the FDA for the prevention or 
treatment of naturally occurring BRD, and, 
4) A comparison arm (placebo or active control) i.e., controlled trials. 
Two levels of screening were used to identify eligible manuscripts. The exact screening 
questions are presented in Supplementary Material 2 and Supplementary Material 3. Conflicts 
between reviewers were resolved by discussion or, when consensus could not be reached, by 
consulting a third reviewer (AOC).   
2.3. Comprehensive reporting assessment 
The comprehensive reporting assessment form (Supplementary Material 4) was based on 
the REFLECT Statement guidelines (O'Connor et al., 2010a). Only the reporting of the first 19 
items of the REFLECT Statement were assessed, as items 20, 21, and 22 were thought to be too 
subjective for simple assessment. Each of the 19 items in the REFLECT Statement was reworded 
into the form of a Yes/No question, for evaluative purposes (e.g. item 10 of REFLECT: "Who 
generated the allocation sequence…?" was modified to: "Did the authors describe who generated 
the allocation sequence?"). Also, some REFLECT items were split into multiple questions 
because they concerned more than one piece of information (e.g. item 10 states "Who generated 
the allocation sequence, who enrolled study units, and who assigned study units to their groups at 
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the relevant level of the organizational structure?"). This item was split into three separate 
subitems (see Table 2). For nomenclature purposes, subitems were given decimal designations, 
i.e., subitem 3 of item 10 is referred to as "item 10.3". As REFLECT assumes that authors 
randomized, an additional question was needed to assess if the authors used the term 
randomization or its variations anywhere in the manuscript, not simply in the title or abstract.  
The comprehensive reporting assessment form was not pre-tested; however, the 
reviewers made minor revisions to the form for clarity during the assessment of the first 6 
references. Two reviewers assessed each publication. If a publication contained a description of 
more than one trial, data from the first relevant trial were extracted. The reviewers were not blind 
to publication dates, because the date on which the study was conducted was part of the 
assessment of reporting (item 14).  
2.4. Statistical analysis 
Prevalence ratios and 95% confidence intervals for each of the items of the REFLECT 
Statement were calculated using OpenEpi (Dean et al., 2013). The mean difference (and 95% 
confidence interval) for the percent of "yes" answers per article was calculated and reported i.e., 
average proportion of "yes" post-2010 minus average proportion of "yes" pre-2010. A positive 
number indicates that the proportion of "yes" responses increased post-2010.  
A forest plot of the pre- and post-2010 prevalence ratios was created using the meta 
package (Schwarzer, 2007) in R 3.4.1 (R-Core-Team, 2017). A plot was also created in R 
comparing the prevalence of checklist items pre-2010 and post-2010. This type of graph allows 
comparison of the point estimates and better illustrates the underlying prevalence of reporting for 
the time periods (pre- and post-2010).  
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The denominator for items 1, 8, 9, and 10.1, was conditioned on randomization i.e., 
studies that reported randomizing the experimental units to the interventions. Studies that 
described quasi-randomization methods i.e.,systematic randomization, were not included in the 
denominator.  
Regarding item 18, because multiplicity takes many forms and the need for adjustment is 
debated, we limited our evaluation of multiplicity to the BRD outcome for treatment arms using 
multiple comparisons methods such as Tukey's test, Duncan's new multiple range test, Fisher's 
least significant difference, and the Bonferroni method. Such studies might naturally be expected 
to consider multiple pairwise comparisons between treatment groups, and therefore a clearer case 
can be made for authors to discuss multiple testing.  
We also anticipated comparing the number of items reported in journals that did and did 
not encourage authors to use the REFLECT Statement after 2010; however, there were too few 
articles published in journals that endorsed the REFLECT Statement to conduct that analysis. We 
also anticipated comparing the count of items reported before and after 2010 for each journal; 
however, this was only feasible for the journal, The Bovine Practitioner, because the remaining 
journals had such sparse data (see Table 3).  
3.  Results  
3.1. Screening references for eligibility 
The number of records found per database searched is reported in Table 1 and 
Supplementary Material 1 for the MEDLINE® and CABI searches, respectively. After de-
duplication in DistillerSR®, 2279 records remained. An additional 48 records were found by 
searching the reference lists of relevant review articles (DeDonder and Apley, 2015a, b; 
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O'Connor et al., 2010b; O'Connor et al., 2016) and The Professional Animal Scientist journal. In 
total, 2327 records underwent screening based on the title and abstract (i.e., Level 1), and of 
these, 1998 were excluded, so that 329 records proceeded to the second level of screening (Level 
2), based on the full text.  
Of the 329 records that underwent screening based on the full text, 234 were excluded 
because:  
1) the full text was not available in English (131 references), 
2) the full text could not be obtained (6 references), 
3) the paper referred to tables that were not in the manuscript itself, preventing direct evaluation 
(1 reference), 
4) the study did not take place in the USA or Canada (47 references), 
5) the study was not published in a journal (20 references), 
6) the study was a review (9 references), 
7) the study was not conducted at a feedlot (11 references), 
8) the study was a challenge trial (1 reference),  
9) the study was not a controlled clinical trial assessing the efficacy of two or more interventions 
against BRD (8 references). 
 A list of all references excluded at Level 2 screening, with the reasons, is given in 
Supplementary Material 5. Therefore, 95 references proceeded to the reporting assessment phase 
of the review (see Supplementary Material 6 for a list of these references).  
3.2. Characteristics of the controlled clinical trials 
Of the 95 manuscripts assessed, 67 were published prior to 2010 (date range: 1971 to 
2009), while 28 were published from 2011 to 2017. The trials were published in a variety of 
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journals with the most common journal being The Bovine Practitioner, a publication of the 
American Association of Bovine Practitioners (AABP). This journal does not provide authors 
with guidance to use any reporting guidelines, including the REFLECT Statement. However, one 
of the authors of the current study, and other groups, have presented at the annual conference for 
the AABP about reporting of controlled clinical trials several times. It is interesting to note that 
Veterinary Therapeutics: Research in Applied Veterinary Medicine was a common publication 
vehicle for many studies prior to 2010. No articles relevant to our survey were published in that 
journal since 2009, which is unsurprising as the journal was discontinued in 2010.  
3.3. Comprehensive reporting assessment 
Reporting of the allocation method at the study level  
The authors reported (in the title, abstract, or methods section) the method used (random 
or non-random) to allocate the experimental units to the interventions in 56/67 (83.6%) and 
28/28 (100%) studies published prior to and following 2010, respectively.  
Fifty-three (79%) of 67 studies published before 2010 and all 28 (100%) papers 
published after 2010 reported using a random allocation method in either the title, abstract, or 
methods section (prevalence ratio (PR) = 1.25; 95% CI (1.09,1.43)). However, it should be noted 
that 8 studies published prior to 2010 and 7 studies published after 2010 reported the term 
"systematic randomization" or variations thereof. Additionally, 5 studies, all published before 
2010, explicitly reported a non-random allocation method (one study used the term "systematic" 
alone; the remaining four studies used alternate allocation, i.e., giving the same intervention to 
every other animal).  
Reporting of REFLECT checklist items  
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The reporting characteristics of the 95 extracted studies for the REFLECT checklist items 
are shown in Table 2. The forest plot displaying the prevalence ratios and corresponding 95% 
confidence intervals is shown in Fig. 1. Fig. 2 depicts the prevalence comparison plot; however, 
precision estimates are not included for clarity, and such information can be derived from Table 
2.  
Overall, there were positive changes post-2010 in the proportion of studies reporting the 
REFLECT items (i.e., All estimates within the 95% confidence interval of the prevalence ratio 
were above 1.) for the following items: reporting of randomization in the title and abstract (item 
1), the description of the setting (item 3.3), specification of the hypothesis (item 5.2), reporting 
of blinding of the person(s) administering the intervention (item 11.1), blinding of outcome 
assessment (item 11.3), reporting whether or not blinding was done (item 11.5), descriptions of 
statistical methods (item 12), and reporting of the dates over which the study took place (item 
14). The reporting of all of the other REFLECT items showed a point estimate of the prevalence 
ratio that was > 1 (apart from item 10.3 (who assigned study units to the interventions), item 13 
(the flow of study units through the study), item 16 (number of study units used in analysis), item 
18 (multiplicity), and item 19 (adverse effects)), although the 95% confidence intervals also 
included values < 1. This suggests a trend toward better reporting in trials published subsequent 
to the publication of the REFLECT Statement as indicated by increasing prevalence. 
Concealment of the allocation sequence (item 9) was not reported for any of the 95 manuscripts.   
Comparing the mean percent of items reported before and after 2010 for each article in 
The Bovine Practitioner resulted in a point estimate for mean difference of +12% (95% CI (-
0.006, 0.25)). The mean percent of items reported before 2010 was 40% and after 2010 was 
52%.  
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Item 18 was only assessed for trials with 3 or more study arms. There were 41 such 
studies in total. Seven of the 41 studies were published after 2010, and none of these described 
the adjustment for multiple pairwise comparisons. Of the 34 studies published prior to 2010, 3 
included adjustment for pairwise comparisons. This should not be interpreted as incorrect 
analysis by the non-reporting studies, as there is a debate as to whether adjustment for multiple 
comparisons is needed (Rothman, 2014). However, there is less debate about the need to report 
whether or not multiple adjustment tests were used to calculate p-values or variance estimates.  
 
4. Discussion 
The results suggest that reporting of published controlled clinical trials that assess 
antibiotic efficacy for the prevention or treatment of BRD is improving, apart from item 10.3, 
(who assigned study units to the interventions), item 13 (the flow of study units through the 
study), item 16 (number of study units used in analysis), item 18 (multiplicity), and item 19 
(adverse effects). 
The largest improvements appear to be occurring in items that already had a moderate 
level of reporting prior to 2010. Items that were poorly reported (i.e., < 5%) prior to 2010 
continue to be poorly reported (items 3.1, 9, 10.2, 10.3, and 11.4), while there was little room for 
improvement for some items, which were already well reported (items 2, 4, and 5.1). This can be 
seen in the prevalence comparison plot (Fig. 2). 
Although there is still room for improvement, it is encouraging that in 100% of studies 
published post-2010, the authors described an allocation method. It is also encouraging that 
authors are including the word "random" or some variation thereof in the title or abstract, which 
makes retrieval of RCTs easier in citation indices. It should be noted that in some of the studies 
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quasi-randomization approaches were used. For instance, "Systematic randomization was used to 
assign 2 animals to receive metaphylaxis (META) for every 1 receiving no metaphylaxis (NO 
META) at processing." (Hendrick et al., 2013, p. 1147), and "Cattle were systematically 
randomized to the treatment groups within each feedlot. A coin was flipped to determine whether 
the first animal in the trial would be treated with florfenicol or tulathromycin. The next animal 
was treated with the other drug. This pattern continued systematically until the desired sample 
size of 250 head/group was achieved." (Van Donkersgoed et al., 2008, p. 277). 
It is important to acknowledge that systematic allocation approaches are not truly 
random, and therefore are less likely to achieve the goals of randomization i.e., exchangeability 
(ignorability) of groups (Greenland and Robins, 2009). While systematic allocation can help to 
ensure that study units are allocated at the desired ratio to each intervention, it does make 
knowledge of the allocation sequence more difficult to conceal, which may introduce bias (Di 
Girolamo et al., 2017; Higgins et al., 2016). For example, if intervention and placebo are given to 
alternate animals as they pass through a processing chute, an investigator may have an 
unconscious bias towards putting thinner-looking animals through the chute such that they will 
receive the preferred intervention. It remains to be studied if quasi-randomization approaches are 
associated with bias in trials in veterinary science. The answer will almost certainly be topic-
specific. For this reason, use of true randomization methods would remove concerns. Because 
random allocation is often confused with haphazard or quasi-random (systematic) allocation, 
reporting of key elements of randomization (such as those required in items 8, 9, and 10) would 
increase confidence that allocation was a valid random procedure (Altman and Bland, 1999).The 
reporting of blinding (use or absence) (item 11.5) has improved overall. That authors are more 
commonly recognizing that good reporting includes reporting that a study was not blinded is a 
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reassuring observation. As with reporting the allocation procedure so that reviewers can 
determine that non-random allocation was employed, this level of transparency enables the 
reader to determine if this is a source of bias, which in some cases it might not be. More 
education of authors, reviewers, and editors is needed on the importance of reporting items 3.2 
(animal eligibility criteria), 5.2 (hypotheses), 6 (primary and secondary outcomes), 10.1 (who 
generated the allocation sequence), 11.1 (blinding of intervention allocation), 17 (effect size and 
precision), and in particular reporting items 3.1 (owner/manager/feedlot eligibility criteria), 7 
(sample size calculations), 8 (method used to achieve randomization), 9 (allocation 
concealment), 10.2 (who enrolled study units), 10.3 (who assigned study units to interventions), 
11.2 (blinding of caregivers), 11.4 (blinding of data analyst), 18 (multiplicity), and 19 (adverse 
events).  
We did not assess the effect of journal endorsement of the REFLECT Statement on 
improved reporting, because only 2 relevant studies were published in endorsing journals after 
2010. The REFLECT group of authors has not devoted a large amount of time to seeking 
endorsement, as our impression was that journals are unsure of the impact of reporting or are 
concerned that authors will be hesitant to submit manuscripts to journals with additional 
submissions requirements. We are unaware of any journal that requires a REFLECT Statement 
checklist with submission.  
As far as we know, this is the first comparative assessment of reporting in veterinary 
science. However, in human health, because the CONSORT reporting guidelines are so widely 
endorsed (at the time of the current study, the count was over 585 journals), the impact of 
reporting guidelines is more readily assessed (CONSORT, 2017). A systematic review published 
in 2012 summarized the results of 53 publications reporting 16,604 RCTs (median per evaluation 
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123 (interquartile range (IQR) 77 to 226) published in a median of six (IQR 3 to 26) journals 
(Turner et al., 2012). That systematic review asked three questions about the:   
1) Completeness of reporting of RCTs published in journals that have and have not endorsed the 
CONSORT Statement,  
2) Completeness of reporting of RCTs published in CONSORT-endorsing journals before and 
after endorsement, or  
3) Completeness of reporting of RCTs before and after the publication of the CONSORT 
Statement (1996 or 2001).  
The latter point is similar to our question of interest, and the findings of that aspect of the 
review were consistent with our study. The authors included statistical significance testing, and 
concluded that six outcomes had statistically significant results, suggesting that these items were 
more completely reported after the publication of the CONSORT Statement. These items were: 
complete reporting of sample size, sequence generation, allocation concealment, statistical 
methods, participant flow, and baseline data. As with our study, there was a strong overall trend 
towards more comprehensive reporting, but there was still room for improvement. 
 O'Connor et al. (2010f) previously assessed and reported comprehensive reporting of 
controlled trials assessing antibiotics used for BRD prior to 2010. The study population was 
slightly different from the one used here (i.e., only individual allocation treatment studies); 
however, the reporting assessment for the pre-2010 studies was very similar. In that study, at the 
study level, 36 (87%) of 41 studies reported using a random method of treatment allocation, 
which was higher than the pre-2010 group in the current study but still lower than the post-2010 
group (28/28: 100%) in the current study. Only 20 of 41 studies reported that staff performing 
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outcome assessment were blinded to treatment group. These results were similar to the current 
study's pre-2010 group (37/67: 55%) compared to 24/28 (86%) post-2010.  
The trends in reporting observed in this study are positive, but they may be attributable to 
many factors independent of the publication of the REFLECT Statement, such as changes to 
journal submission guidelines, improved author knowledge of statistical techniques and options, 
and the overall increased awareness of reporting that goes along with efforts in scientific 
publication.  
A major limitation of this study is that it was observational, rather than the result of an 
RCT itself. Ideally, we would have worked with journals to randomize authors to be required to 
provide a REFLECT checklist upon submission, or randomized reviewers to use the REFLECT 
checklist. Such a study would have been able to control for the numerous confounders discussed 
above that limit the inference we can make about the "impact of REFLECT". Another source of 
bias is that the reviewers in this study were not blinded to the identities of the authors, journal, or 
year of publication of the studies from which data were extracted. This may have resulted in a 
bias away from the null. The steps taken to address this concern were dual independent review 
and open access to the data so that others can determine if they agree with our assessment. 
5.  Conclusions 
There are generally positive trends toward improved reporting in controlled trials that 
assess the use of antibiotic(s) for the treatment and prevention of bovine respiratory disease. 
There is still room for improvement of reporting. We propose that it is critical to determine how 
we can raise awareness of authors to available guidelines that can save time and effort. Education 
of investigators is needed to clarify the difference between "systematic randomization" and true 
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randomization, particularly with respect to the risk of bias when using "systematic random" 
allocation procedures.  
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Figure captions 
 
Fig. 1.  Forest plot of the prevalence ratios and associated 95% confidence intervals of items 1 to 
19 from the REFLECT Statement (O'Connor et al., 2010b) from a survey of controlled clinical 
trials conducted in Canada and/or the USA examining the comparative efficacy of at least one 
FDA-registered antimicrobial against naturally acquired BRD in weaned beef calves. Missing are 
items 2, 3.1, 9, 10.3, 11.4, and 18 because they had at least 1 zero value in the 2 X 2 table.   
 
Fig. 2.  Prevalence comparison plot of items 1 to 19 from the REFLECT Statement (O'Connor et 
al., 2010b) from a survey of controlled clinical trials conducted in Canada and/or the USA 
examining the comparative efficacy of at least one FDA-registered antimicrobial against 
naturally acquired BRD in weaned beef calves. The y-axis represents the post-2010 prevalence 
of the REFLECT item, and the x-axis represents the pre-2010 prevalence of the REFLECT item. 
The dotted line indicates equivalent prevalence. Items above the dotted line had a higher 
prevalence post-2010 compared to pre-2010, while below the dotted line, the prevalence of that 
item is lower post-2010 compared to pre-2010. 
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Supplementary Materials 
Supplementary Material 1. Results of a search conducted in CABI (CAB Abstracts® and 
Global Health®) (Web of ScienceTM) on 15 April 2017 for a survey of clinical trials conducted 
in Canada and/or the USA examining the comparative efficacy of at least one FDA-registered 
antimicrobial against naturally acquired BRD in weaned beef calves. The search dates were 
restricted to 1970 to Present (2017), and there were no language or document-type restrictions.  
 
Search 
no. 
 
Search string No. hits
 
1 
 
TS=(beef OR bovine OR calf OR calves OR cattle OR cow OR cows OR 
dairy OR Hereford OR Holstein OR ruminant OR ruminants OR steer OR 
steers) 
 
933,061
2 TS=(bovine respiratory disease OR Bovine viral diarrhea OR Bovine viral diarrhea virus OR undifferentiated fever OR BRD OR BVD OR BVDV 
OR Haemophilus somnus OR Histophilus somni OR IBR OR Infectious 
bovine rhinotracheitis OR Mannheimia hemolytica OR Pasteurella 
multocida OR Pasteurellosis OR respiratory disease OR undifferentiated 
bovine respiratory disease) 
 
90,838
3 TS=(amoxicillin OR ampicillin OR antibiotic OR antibiotics OR antimicrobial OR antimicrobials OR erythromycin OR ceftiofur OR 
cloxacillin OR danofloxacin OR enrofloxacin OR florfenicol OR 
gentamycin OR lincomycin OR oxytetracycline OR penicillin OR 
spectinomycin OR sulfamethoxazole OR tilmicosin OR trimethoprim OR 
tulathromycin OR tylosin OR gamithromycin OR danofloxacin OR 
tildipirosin) 
 
168,066
4 #1 AND #2 AND #3  
2193
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Supplementary Material 2. First-level relevance screening question (based on the title and/or 
abstract) for a survey of clinical trials conducted in Canada and/or the USA examining the 
comparative efficacy of at least one FDA-registered antimicrobial against naturally acquired 
BRD in weaned beef calves. 
Question text 
 
Answer type Answer options 
 
Q1. Does the title or abstract 
indicate primary research 
(published in journals rather 
than FDA submissions or 
technical reports) describing a 
trial for an FDA-registered 
treatment of BRD in feedlot 
calves within North America 
(Canada and/or USA only)? 
 
 
Radio 
 
Yes 
No  
Can't tell (unclear) 
Can't tell (no abstract) 
Potentially relevant review 
Comments 
 
Text  
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Supplementary Material 3. Second-level relevance screening questions (based on the full text 
of the reference) for a survey of clinical trials conducted in Canada and/or the USA examining 
the comparative efficacy of at least one FDA-registered antimicrobial against naturally acquired 
BRD in weaned beef calves. 
Question text 
 
Answer type Answer options 
Q1. Is the full text available in 
English? If not in English, 
please indicate language. 
Radio Yes 
No (not in English) 
No (unable to obtain .pdf of full 
text) 
  No (Reference cites tables that were 
not in the manuscript.) 
   
Q2. Does the trial describe 
primary research on weaned 
beef calves in the USA and/or 
Canada on a cattle feedlot 
published in a journal?   
 
Radio Yes 
No 
 
Q3. Does the study have 
multiple arms with at least one 
arm as an FDA-registered 
antibiotic(s) available in the 
USA or Canada? It can be 
either metaphylaxis to prevent 
BRD or treatment for BRD. 
Radio Yes 
No 
Unclear 
   
   
Additional comments 
 
Text  
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Supplementary Material 4. Reporting assessment form for a survey of clinical trials conducted 
in Canada and/or the USA examining the comparative efficacy of at least one FDA-registered 
antimicrobial against naturally acquired BRD in weaned beef calves. This form is based on the 
REFLECT Statement (O'Connor et al. 2010). 
 
Q1. In the Title and/or Abstract, did the investigators report that the study units were randomly 
allocated to the interventions (e.g. "random allocation", "randomized", or "randomly assigned")? 
 Yes 
 No  
 Unclear 
 
Q2. In the Introduction, did the investigators provide a scientific background of the topic and a 
rationale (explanation) for the study? 
 Yes 
 No 
 Unclear 
 
Q3. In the Methods, did the investigators report eligibility criteria for 
owner(s)/manager(s)/feedlot(s) and study units (i.e., how they were selected) at each level of the 
organizational structure, and did they describe the settings and locations where the data were 
collected? 
 Yes (animal and feedlot eligibility criteria were reported and setting was described) 
 No (animal and feedlot eligibility criteria were reported but setting was not described) 
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 No (animal and feedlot eligibility criteria not reported but setting was described) 
 No (neither animal/feedlot eligibility criteria were reported nor was setting described 
 Unclear 
 
Q4. In the Methods, did the investigators give precise details of the interventions intended for 
each group, the level at which the intervention was allocated, and how and when interventions 
were actually administered? Dose and route are the minimum information required. 
 Yes (fully reported) 
 No (list details missing) ______________________ 
 Unclear 
 
Q5. Did the investigators report the specific objectives and hypotheses of the study (a statistical 
hypothesis, not a working hypothesis, which is like an objective)? 
 Yes (objectives and hypotheses reported) 
 Yes (only objectives were reported, not hypotheses) 
 Yes (only hypotheses were reported, not objectives) 
 No (neither hypotheses nor objectives were reported) 
 Unclear 
 
Q6. Did the investigators give clearly defined primary and secondary outcome measures and the 
levels at which they were measured, and, when applicable, any methods used to enhance the 
quality of the measurements? The primary outcome is the one based on which the sample size 
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was calculated. In the absence of sample size calculations, authors must use the term "primary" 
or "main" to indicate a primary objective. 
 Yes 
 No 
 Unclear 
 
Q7. Did the investigators report how the sample size was determined and, when applicable, give 
an explanation of any interim analyses and stopping rules? Sample-size considerations should 
include sample-size determinations at each level of the organizational structure and the 
assumptions used to account for any non-independence among groups or individuals within a 
group. 
 Yes 
 No 
 Unclear 
 
Q8. Did the investigators report the method used to generate the random allocation sequence at 
the relevant level of the organizational structure, including details of any restrictions (e.g., 
blocking, stratification)? 
 Yes 
 No 
 Unclear 
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Q9. Did the investigators report the method used to implement the random allocation sequence at 
the relevant level of the organizational structure, (e.g. numbered containers), clarifying whether 
the sequence was concealed until interventions were assigned? 
 Yes 
 No 
 Unclear 
 
Q10. Did the investigators report who generated the allocation sequence, who enrolled study 
units, and who assigned study units to their groups at the relevant level of the organizational 
structure? 
 Yes 
 No (Indicate what's missing) ______________________ 
 Unclear 
 
Q11. Did the investigators report whether or not those administering the interventions, 
caregivers, and those assessing the outcomes were blinded to group assignment? If done, was the 
success of blinding evaluated? Did the investigators provide justification for not using blinding if 
it was not used? Check all that apply: 
 Yes (people giving the intervention) 
 Yes (caregivers. The term "caregivers" or "caretakers" or "care takers" must be used.) 
 Yes (outcome assessors) 
 Yes (people analyzing the data) 
 No (Investigators did not report whether or not anyone was blinded.) 
Totton et al./Revised Manuscript/Page 35 
 
 Unclear 
 
Q12. Were statistical methods used to compare groups for all BRD outcome(s)? Did the 
investigators clearly state the level of statistical analysis and methods used to account for the 
organizational structure (where applicable)? Were the methods for additional analyses, such as 
subgroup analyses and adjusted analyses reported? (Only consider the BRD outcomes.) 
 Yes 
 No (Specify what's missing/not accounted for) ____________ 
 Unclear 
 
Q13. In the Results, did the investigators report the flow of study units through each stage for 
each level of the organization structure of the study? A diagram is strongly recommended. 
Specifically, for each group, did the investigators report the numbers of study units randomly 
assigned, receiving intended treatment, completing the study protocol, and analyzed for the 
primary outcome (The primary outcome is the one for which the sample size was calculated.)? 
Did the investigators describe protocol deviations from study as planned, together with reasons, 
if applicable? 
 Yes 
 No 
 Unclear 
 
Q14. Did the investigators report dates defining the periods of recruitment and follow-up? 
 Yes 
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 No 
 Unclear 
 
Q15. Did the investigators report the baseline demographic and clinical characteristics of each 
group, explicitly providing information for each relevant level of the organizational structure? 
Data should be reported in such a way that secondary analysis, such as risk assessment, is 
possible. If the study was done on 3 feedlots, we want the results reported by feedlot, not pooled. 
 Yes 
 No 
 Unclear 
 
Q16. Did the investigators report the number of study units (denominator) in each group 
included in each analysis? Did the investigators state the results in absolute numbers when 
feasible (e.g., 10/20, not 50%)? 
 Yes 
 No 
 Unclear 
 
Q17. Did the investigators, for the BRD outcome(s) only, report a summary of results for each 
group, accounting for each relevant level of the organizational structure, and the estimated effect 
size and its precision (e.g., 95% confidence interval): 1) on the primary outcome, if there was 
one (primary outcome is the one for which sample size calculation was made) and 2) if not, 
report on the main health outcome (likely BRD or 1st pull rate)? 
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 Yes 
 No 
 Unclear 
 
Q18. Did the investigators address multiplicity by reporting any other analyses performed, 
including subgroup analyses and adjusted analyses, indicating those pre-specified and those 
exploratory? 
 Yes (specify) ______________________ 
 No 
 Unclear 
 
Q19. Did the investigators report all important adverse events or side effects in each intervention 
group? If they didn't report anything, the answer is "No". They need to separate it out by group; 
if it says 3 adverse events BUT they don't report how many per group then the answer is "No". 
 Yes 
 No 
 Unclear  
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Supplementary Material 5. References excluded at the second level of screening (based on the 
full text) for a survey of clinical trials conducted in Canada and/or the USA examining the 
comparative efficacy of at least one FDA-registered antimicrobial against naturally acquired 
BRD in weaned beef calves.  
Reference Reason for exclusion 
 
D Nash. A comparison of three therapeutic 
programs for the treatment of shipping fever 
in weaned calves. Bovine Respiratory 
Disease: A Symposium; Ed by R Loan, 
College Station, Texas A&M University 
Press 1984. 471-472. 
 
Not published in a journal 
Enrico Fiore, Leonardo Armato, Massimo 
Morgante, Michele Muraro, Matteo Boso, 
Matteo Gianesella. Methaphylactic effect of 
tulathromycin treatment on rumen fluid 
parameters in feedlot beef cattle. Canadian 
journal of veterinary research. 2016. 80: 60-
5. 
 
Study occurred in Italy. 
Robert G. Nutsch, Terry L. Skogerboe, 
Kathleen A. Rooney, Daniel J. Weigel, 
Kimberly Gajewski, Kelly F. Lechtenberg. 
Comparative efficacy of tulathromycin, 
tilmicosin, and florfenicol in the treatment 
of bovine respiratory disease in stocker 
cattle. Veterinary Therapeutics: research in 
applied veterinary medicine. 2005. 6:167-
79. 
 
Study took place on pastures, not 
feedlot. 
B. Elitok, O. M. Elitok. Clinical efficacy of 
carprofen as an adjunct to the antibacterial 
treatment of bovine respiratory disease. 
Journal of veterinary pharmacology and 
therapeutics. 2004. 27:317-20. 
 
Turkish study 
Norbert K. Chirase, L. Wayne Greene, 
Charles W. Purdy, Raymond W. Loan, Brent 
W. Auvermann, David B. Parker, Earl F. 
Walborg, Donald E. Stevenson, Yong Xu, 
James E. Klaunig. Effect of transport stress 
The authors did not assess the 
relationship between antimicrobial 
treatment and a BRD outcome. 
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on respiratory disease, serum antioxidant 
status, and serum concentrations of lipid 
peroxidation biomarkers in beef cattle. 
American journal of veterinary research. 
2004. 65:860-4. 
 
Beth Hibbard, Edward J. Robb, Michael D. 
Apley, S. Theodore Chester, Kenneth J. 
Dame. Feedlot performance of steers treated 
concurrently with ceftiofur crystalline-free 
acid subcutaneously in the posterior aspect 
of the ear and a growth-promoting implant. 
Veterinary Therapeutics : research in 
applied veterinary medicine. 2002. 3:252-
61. 
 
Study had multiple arms and at least 
one arm is an FDA-registered 
antibiotic(s) available in the USA or 
Canada? No 
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dans le traitement des bronchopneumonies 
infectieuses enzootiques des jeunes bovins 
eleves en lots. Bulletin des G.T.V.. 1996. Pp. 
21-25. 
 
Study in French 
T. A. Hughes, G. A. Tice. An evaluation of 
the use of Micotil tilmicosin , 
metaphylactically, on arrival, for calf 
pneumonia. Irish Veterinary Journal. 1996. 
49:622-624. 
 
Not a US or Canadian study 
P. W. D. Lockwood, V. D. De Haas, T. M. 
S. Katz, K. J. Varma. Clinical efficacy of 
florfenicol in the treatment of shipping fever 
Study in Spanish 
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in cattle in the USA Eficacia clinica del 
florfenicol en el tratamiento del sindrome 
respiratorio bovino en Norteamerica. 
Medicina Veterinaria. 1996. 13:34...38. 
 
M. Kondracki, E. Malinowski, D. Bednarek, 
M. Nadolny. Influence of Lydium-KLP 
preparation lysozyme on the efficacy of 
antibiotics in respiratory and digestive 
diseases in calves Wplyw Lydium-KLP na 
skutecznosc antybiotykoterapii w 
schorzeniach pluc i przewodu pokarmowego 
cielat. Zycie Weterynaryjne. 1996. 71:346-
348. 
 
Study in Polish 
J. A. Kennedy. The effects of Re-17 mutant 
Salmonella Typhimurium bacterin-toxoid on 
bovine respiratory disease in feedlot heifers. 
Agri-Practice. 1995. 16:29-31. 
 
Not a US or Canadian study 
P. W. Lockwood, V. de Haas, T. Katz, K. J. 
Varma. Therapeutic efficacy of florfenicol 
in treating respiratory diseases of cattle in 
Europe and North America Efficacia 
terapeutica del florfenicolo nel trattamento 
della malattia respiratoria dei bovini, in 
Europa e nel Nord America. Atti della 
Societa Italiana di Buiatria. 1995. 27:477-
481. 
 
Study in Italian 
C. Young. Antimicrobial metaphylaxis for 
undifferentiated bovine respiratory disease. 
Compendium on Continuing Education for 
the Practicing Veterinarian. 1995. 17:133-
142. 
 
Not a clinical trial 
C. Pagani. Florfenicol in the treatment of 
respiratory diseases of cattle Il florfenicolo 
nella terapia della malattia respiratoria 
bovina. Obiettivi e Documenti Veterinari. 
1995. 16:58-59. 
 
Study in Italian 
T. R. Ames, S. Srinand, S. K. Maheswaran. 
Making the antibiotic choice for treating 
bovine respiratory disease. Proceedings of 
the Twenty Seventh Annual Convention 
Not a clinical trial 
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American Association of Bovine 
Practitioners, Pittsburgh, Pennsylvania, 
USA, September 22-25, 1994. 1995. Pp. 
152-156 
H. Navetat, D. Concordet, P. Lockwood, A. 
Madelenat, J. Espinasse. Efficacy of 
florfenicol in the therapy of acute 
pneumonia in housed beef calves Efficacite 
du florfenicol dans le traitement des 
bronchopneumonies infectieuses 
enzootiques des broutards (BPIE). Revue de 
Medecine Veterinaire. 1995. 146:567-574. 
 
Study in French 
M. J. Jovanovic, S. Markovic, D. Burcul, Z. 
Damnjanovic, N. Milic, D. Krnjajic, D. 
Milcic, A. Nitovski, V. Mladenovic. 
Comparative studies on various 
chemotherapeutic agents (Urotovet, Tilovet, 
Oxyvet) in treating bronchopneumonia in 
calves and heifers Komparativno ispitivanje 
razlicitih hemoterapeutika u lecenju 
bronhopneumonije teladi i junadi. 
Veterinarski Glasnik. 1995. 49:463-470. 
 
Study in Serbian 
P. E. J. Bols, A. de Kruif. A clinical 
comparison of two injectable 
oxytetracycline preparations for the 
treatment of pneumonia in calves. 
Veterinary Quarterly. 1995. 17:6-8. 
 
Not a US or Canadian study 
L. Fodor, J. Varga, F. Gallovitsch, I. 
Horvath-Papp, G. Miklos, A. Lajcsak, A. 
Harmath. Pneumonia in calves - drug 
therapy with tilmicosin injection (Micotil). 
II Borjak tudogyulladasanak gyogykezelese 
tilmikozin injekcioval. Rovid masodkozles. 
Magyar Allatorvosok Lapja. 1994. 49:304-
305. 
 
Study in Hungarian 
T. Winter, W. Hofmann. Treatment of 
chronic bronchopneumonia in calves with 
the macrolide antibiotic tilmicosin Zur 
Behandlung chronischer 
Bronchopneumonien bei Kalbern mit dem 
Makrolidantibiotikum Tilmicosin (Micotil). 
Praktische Tierarzt. 1994. 75:302...308. 
Study in German 
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L. Ivandija, L. Pavesic, B. Dostal, L. 
Vibovec, D. Stritof. Control of respiratory 
diseases in calves by a combination of 
antimicrobial and nutritional substances 
Suzbijanje bolesti disnog sustava u teladi 
kombinacijom antimikrobnih i nutritivnih 
tvari. Praxis Veterinaria (Zagreb). 1994. 
42:173-182. 
 
Study in Croatian 
H. A. Gibbs, A. Bottner. The use of 
cefquinome in the treatment of respiratory 
disease in cattle. Proceedings 18th World 
Buiatrics Congress: 26th Congress of the 
Italian Association of Buiatrics, Bologna, 
Italy, August 29-September 2, 1994. Volume 
1. 1994. Pp. 535-538. 
 
Not published in a journal 
P. W. Lockwood, V. de Haas, T. Katz, K. J. 
Varma. Clinical efficacy of florfenicol in the 
treatment of bovine respiratory disease in 
Europe and North America. Proceedings 
18th World Buiatrics Congress: 26th 
Congress of the Italian Association of 
Buiatrics, Bologna, Italy, August 29-
September 2, 1994. Volume 1. 1994. Pp. 
551-554. 
 
Not published in a journal 
T. Richard, J. Buisson, P. Mathevet, J. 
Delannoy, P. Delas, F. Longo. Clinical 
efficacy of a long acting spiramycin 
injectable formulation for the treatment of 
bovine infectious enzootic 
bronchopneumonia. Proceedings 18th World 
Buiatrics Congress: 26th Congress of the 
Italian Association of Buiatrics, Bologna, 
Italy, August 29-September 2, 1994. Volume 
1. 1994. Pp. 563-566. 
 
Not a US or Canadian study 
J. Espinasse, H. Navetat, B. Dellac, C. Rizet. 
Efficacy of enrofloxacin in the treatment of 
infectious enzootic bronchopneumonia 
(BPIE) in young cattle Efficacite de 
l'enrofloxacine dans le traitment des 
bronchopneumonies infectieuses 
enzootiques (BPIE) des jeunes bovins. 
Study in French 
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Proceedings 18th World Buiatrics 
Congress: 26th Congress of the Italian 
Association of Buiatrics, Bologna, Italy, 
August 29-September 2, 1994. Volume 1. 
1994. Pp. 579-582. 
 
S. Cakala, W. Kiczka, M. Kondracki, E. 
Malinowski, J. Pilaszek. Evaluation of 
Lydium KLP+ - lysozyme dimer used for 
the first time in the treatment of 
bronchopneumonia and gastroenteritis in 
calves. Proceedings 18th World Buiatrics 
Congress: 26th Congress of the Italian 
Association of Buiatrics, Bologna, Italy, 
August 29-September 2, 1994. Volume 1. 
1994. Pp. 607-610. 
 
Not a feedlot study 
R. Highland, D. Copeland, J. Davidson, T. 
TerHune, K. Lechtenberg, E. Johnson, D. 
Miles, M. Apley, M. Wray. Dose 
determination and clinical evaluation of the 
efficacy of enrofloxacin injectable solution 
in the treatment of bovine respiratory 
disease. Proceedings 18th World Buiatrics 
Congress: 26th Congress of the Italian 
Association of Buiatrics, Bologna, Italy, 
August 29-September 2, 1994. Volume 1. 
1994. Pp. 627-630. 
 
Not published in a journal 
B. H. Laurisden, J. Jorgensen, L. Olesen, T. 
Nell. Metaphylactic treatment against 
enzootic pneumonia of calves. Proceedings 
18th World Buiatrics Congress: 26th 
Congress of the Italian Association of 
Buiatrics, Bologna, Italy, August 29-
September 2, 1994. Volume 1. 1994. 
#volume#:713-716. 
 
Not a US or Canadian study 
J. R. D. Allison, J. Brebner, R. L. Jones. 
Clavulanate-potentiated amoxycillin for the 
treatment of bovine pneumonic 
pasteurellosis. Proceedings 18th World 
Buiatrics Congress: 26th Congress of the 
Italian Association of Buiatrics, Bologna, 
Italy, August 29-September 2, 1994. Volume 
2. 1994. Pp. 1335-1338. 
Not a US or Canadian study 
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M. J. Jovanovic, S. Stojicevic, V. Bozovic, 
R. Asanin, N. Milic, S. Markovic, Z. 
Damnjanovic, D. Milcic, D. Rasic. Use of 
Urotovet (hexamine hydrorhodanide) in the 
treatment of enzootic pneumonia in calves 
Primena "Urotoveta" (hexamin-
hidrorodanida) u lecenju enzootske 
pneumonije teladi. Veterinarski Glasnik. 
1994. 48:861-867. 
 
Study in Serbo-Croatian 
Z. Kuleta, J. Borzemski, J. Wosek. Clinical 
evaluation of efficacy of clenbuterol in the 
treatment of respiratory diseases in calves 
Ocena kliniczna preparatu Clenbuterol w 
leczeniu schorzen ukladu oddechowego u 
cielat. Acta Academiae Agriculturae ac 
Technicae Olstenensis, Veterinaria. 1993. P. 
103-112. 
 
Study in Polish 
R. A. Smith, D. R. Gill, M. T. van 
Koevering. Effects of tilmicosin or ceftiofur 
on health and performance of stressed 
stocker cattle. Animal Science Research 
Report, Agricultural Experiment Station, 
Oklahoma State University. 1993. Pp. 308-
311. 
 
Not published in a journal 
H. P. Heckert, W. Hofmann. Auxiliary 
effect in an antihistamine (Benadryl-
parenteral) in the treatment of BRSV 
infection in cattle Klinische Hinweise auf 
eine unterstutzende Wirkung von 
Antihistaminika (Benadryl-parenteral) bei 
der Behandlung der RSV-Infektion des 
Rindes. Berliner und Munchener 
Tierarztliche Wochenschrift. 1993. 106:230-
235. 
 
Study in German 
H. Navetat. Efficacy of long acting 
Terramycin (oxytetracycline) in treating 
broncho-pneumonia in calves Efficacite de 
la Terrmycine longue action dans le 
traitment des broncho-pneumonies 
infectieuses enzootiques (BPIE) des jeunes 
bovins. Bulletin Mensuel de la Societe 
Study in French 
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Veterinaire Pratique de France. 1993. 
77:339...351. 
 
P. Jessen, O. Kristiansen, F. O. Madsen. 
Baquiloprim/sulfadimidine in calves and 
young cattle. Oral treatment of enzootic 
pneumonia and infectious pododermatitis 
Baquiloprim/sulfadimidin (Diprinovet vet.) 
til kalve og ungkreaturer. Oral behandling af 
enzootisk pneumoni og klovbrandbyld. 
Dansk Veterinartidsskrift. 1993. 76:796-798. 
 
Study in Danish 
K. Lechtenberg. Fighting BRD bovine 
respiratory disease: mass medicating stocker 
calves. Large Animal Veterinarian. 1993. 
48:6-7. 
 
Not a clinical trial 
C. Faixa, C. Alaman. Field study: evaluation 
of the efficacy of injectable amoxicillin-
clavulanic acid, with a single antibiotic 
treatment or combined with tylosin 
Experiencia de campo: evaluacion de la 
eficacia de la amoxicilina-acido clavulanico 
inyectable, como unico tratamiento 
antibiotico o combinado con tilosina, frente 
a una combinacion multiple antibiotica-
antiinflamatoria. Medicina Veterinaria. 
1993. 10:610-615. 
 
Study in Spanish 
G. Galli, W. Cabrini, A. Conforti, M. Fin. 
Efficacy of Micotil (tilmicosin) given as a 
single injection to treat respiratory 
conditions in beef cattle Efficacia di Micotil 
in unica somministrazione, nel trattamento 
delle forme respiratorie del vitellone. 
Obiettivi e Documenti Veterinari. 1993. 
14:59-64. 
 
Study in Italian 
D. Schimmel. Efficacy of cefquinome 
against Pasteurella haemolytica in vitro and 
in vivo, and against Pasteurella multocida in 
vitro. Pasteurellosis in production animals: 
an International Workshop sponsored by 
ACIAR held at Bali, Indonesia, 10-13 
August 1992. 1993. Pp. 191-192. 
 
Not a US or Canadian study 
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J. I. Sakai, M. Koya, S. Abe. Efficacy of 
Bay Vp2674 (enrofloxacin) injection in 
treating pneumonia in calves on a fattening 
farm. Tohoku Journal of Veterinary Clinics. 
1993. 16:5-12. 
 
Study in Japanese 
Combination of oxytetracycline and 
sulfadimethoxine Association 
oxytetracycline + sulfadimethoxine. Action 
Veterinaire. 1992. Page 11. 
 
Study in French 
M. T. van Koevering, D. R. Gill, R. A. 
Smith, W. J. Hill, R. L. Ball. Mass 
medication treatments for newly arrived 
stocker cattle. Animal Science Research 
Report, Agricultural Experiment Station, 
Oklahoma State University. 1992. Pp. 333-
338. 
 
Not published in a journal 
M. T. van Koevering, D. R. Gill, F. N. 
Owens, R. A. Smith, R. L. Ball. Effects of 
dosage of ceftiofur on health and 
performance of shipping stressed stocker 
cattle. Animal Science Research Report, 
Agricultural Experiment Station, Oklahoma 
State University. 1992. Pp. 339-341. 
 
Not published in a journal 
H. Grunau. Field trial of tilmicosin for 
endemic bronchopneumonia of beef calves 
Feldstudie zur klinischen Erprobung des 
neuen Makrolidantibiotikums Tilmicosin in 
der Therapie der Enzootischen 
Bronchopneumonie von Mastrindern. 
Feldstudie zur klinischen Erprobung des 
neuen Makrolidantibiotikums Tilmicosin in 
der Therapie der Enzootischen 
Bronchopneumonie von Mastrindern. 1992. 
103 pp. 
 
Study in German 
K. Anusz, G. Nowak, J. Kita. Treatment of 
respiratory diseases of calves with 
cephalosporin ceftiofur Leczenie 
cefalosporyna ceftiofur syndromu chorob 
ukladu oddechowego cielat (BRD). 
Medycyna Weterynaryjna. 1992. 48:26-29. 
 
Study in Polish 
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L. Rubio, M. Gutierrez, H. Garcini. 
Importance of early treatment with 
oxymycin (oxytetracycline dihydrate) in 
bronchopneumonia of calves Importancia 
del tratamiento precoz con oximicina en las 
broncopneumonias del ternero. Revista de 
Salud Animal. 1992. 14:153-158. 
 
Study in Spanish 
K. Tugut, O. Ergani, A. Basoglu. 
Therapeutic effects of enrofloxacin on 
pneumonic and diarrhoeic calves. Veteriner 
Fakultesi Dergisi, Selcuk Universitesi. 1992. 
8:55-57. 
 
Not a US or Canadian study 
J. W. Allen, K. G. Bateman, L. Viel, S. 
Rosendal, P. E. Shewen. The microbial flora 
of the upper and lower respiratory tracts of 
feedlot calves with undifferentiated bovine 
respiratory disease. Bovine Practitioner. 
1991. Pp. 162-168. 
 
Not a clinical trial 
C. Moldoveanu, D. Pasca, A. Ionescu, V. 
Secasiu, R. Zabava. Comacyclin - an 
antiinfective veterinary drug made by 
combining tetracycline and erythromycin. II. 
Preliminary research on tolerance and 
therapeutic efficiency Comaciclin - 
medicament antiinfectios de uz veterinar 
obtinut prin asocierea tetraciclinei cu 
eritromicina. Medicamentul Veterinar. 1991. 
Pp. 21-26. 
 
Study in Romanian 
M. A. Imaz, A. Palomo, X. Simon, J. 
Fernandez de Aragon, M. Sitjar. Treatment 
of respiratory diseases of calves with 
ceftiofur sodium. Field trial Tratamiento de 
las afecciones respiratorias de los terneros 
con ceftiofur sodico. Estudio de campo. 
Medicina Veterinaria. 1991. 8:349...356. 
 
Study in Spanish 
G. A. Pakhomov. Results of treatment of 
calves with bronchopneumonia. Novoe v 
diagnostike, lechenii i profilaktike boleznei 
molodnyaka sel'skokhozyaistvennykh 
zhivotnykh. 1991. Pp. 53-56. 
 
Study in Russian 
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J. Hunkenmoller. Comparison of the 
efficacy of enrofloxacin and gentamicin in 
cattle with infections of the respiratory and 
digestive systems, under clinic conditions 
and in practice Vergleichende 
Untersuchungen zur Wirksamkeit von 
Enrofloxacin (Baytril, BAY VP 2647, 
Bayer) und Gentamicin bei Infektionen des 
Atmungs- und Verdauungsapparates des 
Rindes in Klinik und Praxis. Vergleichende 
Untersuchungen zur Wirksamkeit von 
Enrofloxacin (Baytril, BAY VP 2647, Bayer) 
und Gentamicin bei Infektionen des 
Atmungs- und Verdauungsapparates des 
Rindes in Klinik und Praxis. 1991. 135 pp. 
 
Study in German 
C. R. Clarke, G. E. Burrows, T. R. Ames. 
Therapy of bovine bacterial pneumonia. 
Veterinary Clinics of North America, Food 
Animal Practice. 1991. 7:669-694. 
 
Not a clinical trial 
C. J. Giles, W. T. R. Grimshaw, D. J. 
Shanks, D. G. Smith. Efficacy of 
danofloxacin in the therapy of acute 
bacterial pneumonia in housed beef cattle. 
Veterinary Record. 1991. 128:296-300. 
 
Not a US or Canadian study 
J. J. Andrews, L. J. Hoffman. Effects of sub-
mic levels of chlortetracycline on the 
development of Haemophilus somnus 
pneumonia in calves. American Association 
of Veterinary Laboratory Diagnosticians: 
Abstracts 33rd Annual Meeting, Denver, 
Colorado, October 7-9, 1990. 1990. Pp.64. 
 
Challenge study on dairy calves 
S. Simko. Evaluation of a tylosin and 
sulfadimidine antimicrobial premix (Tynil, 
Biotika) in the respiratory syndrome of 
calves Zhodnotenie ucinku 
protimikroboveho premixu tylozinu a 
sulfadimidinu (Tynil, Biotika) pri 
respiracnom syndrome teliat. Biologizace a 
Chemizace Zivocisne Vyroby, Veterinaria. 
1990. 26:305-311. 
 
Study in Slovakian 
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M. Switala, R. Znaniecki, S. Chomentowski, 
T. Hebel, W. Nowacki, B. Obminska-
Domoradzka. Use of levamisole and 
nitrogen mustard and antibiotics in the 
treatment of enzootic bronchopneumonia in 
calves Zastosowanie lewamizolu i 
nitrogranulogenu w skojarzeniu z anty 
biotykami w leczeniu enzootycznej 
bronchopneumonii cielat. Medycyna 
Weterynaryjna. 1990. 46:38-41. 
 
Study in Polish 
G. C. Signorini, L. Bonanomi, M. Gabrielli. 
Treatment and prevention of respiratory 
syndromes in the calf: treatment with 
acetylcysteine Terapia e profilassi delle 
sindromi respiratorie del vitello: trattamento 
con acetilcisteina. Obiettivi e Documenti 
Veterinari. 1990. 11:15-20. 
 
Study in Italian 
J. K. Merrill, L. V. Thompson. Respiratory 
diseases of cattle; Micotil, a new macrolide 
antibiotic Malattie respiratorie del bovino; 
Micotil: un nuovo antibiotico macrolidico. 
Summa. 1990. 7:156-158. 
 
Study in Italian 
B. Luitjens. Aetiology and treatment of 
bronchopneumonia in calves and young 
cattle Untersuchungen zu Atiologie und 
Therapie bronchopneumonischer 
Erkrankungen bei Kalbern und Jungrindern. 
Untersuchungen zu Atiologie und Therapie 
bronchopneumonischer Erkrankungen bei 
Kalbern und Jungrindern. 1990. 121 pp. 
 
Study in German 
A. F. Mogilenko. Use of nonspecific 
immunostimulation in treatment of calves 
with bronchopneumonia. Veterinarnaya 
Nauka - Proizvodstvu. 1990. 28:84-90. 
 
Study in Russian 
H. Samanc, Z. Damnjanovic, S. Markovic, 
B. Jonic, S. Filipovic, D. Pavlovic. Use of 
Excenel (ceftiofur sodium) to treat calves 
with the respiratory syndrome Primena leka 
"Excenel" (ceftiofur-Na) u lecenju teladi sa 
respiratornim sindromom. Veterinarski 
Glasnik. 1990. 44:513-519. 
Study in Serbo-Croatian 
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J. P. Alzieu, H. J. Bichet, B. Levrier, F. van 
Gool, R. Bayle, M. Libersa, J. Espinasse. 
Efficacy and long-lasting activity of 
spiramycin in young beef cattle with 
infectious enzootic broncho-pneumonia. 
Bovine Practitioner. 1989. Pp. 38-41. 
 
Not a US or Canadian study 
M. Imaz, X. Simon, J. Fernandez de Aragon. 
A new cephalosporin for the treatment of 
bovine respiratory syndrome Una nueva 
cefalosporina para el tratamiento del 
sindrome respiratorio bovino. Medicina 
Veterinaria. 1989. 6:519...533. 
 
Study in Spanish 
W. Baumgartner, R. Pangerl. Efficacy of 
oral enrofloxacin (Baytril) solution in calves 
with respiratory disease Zur Wirksamkeit 
der oralen Baytril-Losung bei 
Atemwegserkrankungen des Kalbes. Tagung 
der Fachgruppe "Rinderkrankheiten", 
Berlin, 14. und 15. February 1989. 1989. 
Pp. 170-175. 
 
Study in German 
E. Muylle, T. Picavet. Comparison of the 
effect of Ventipulmin (clenbuterol) with and 
without trimethoprim-sulfadiazine on lung 
function in calves with bronchopneumonia 
Vergleichende Untersuchungen zur Wirkung 
von Ventipulmin und einer Ventipulmin + 
TMP/S-Kombination auf die 
Lungenfunktion bronchopneumonisch 
erkrankter Kalber. Tierarztliche Umschau. 
1989. 44:212-214. 
 
Study in German 
I. M. Sakhatskii. Intrapulmonary 
administration of antibiotics in calves with 
bronchopneumonia. Veterinariya, Moscow. 
1989. Pp. 59-60. 
 
Study in Russian 
G. A. Krasnikov, A. M. Tsymbal, N. V. 
Klenina, V. M. Zhuravlev, N. N. Sosa, K. E. 
Konarzhevskii, V. S. Antonov, E. P. 
Lebedeva, V. I. Tertyshnik, N. I. Korchan, 
A. Yu Kassich, V. B. Gur'eva, R. K. 
Belokon, L. V. Chebanyuk, N. D. 
Study in Russian 
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Kuz'menko. Effect of immunomodulators on 
the immune system of calves with 
bronchopneumonia. Veterinariya (Moskva). 
1989. Pp. 30-32. 
V. Vukovic, P. Krdzalic, M. Aleksic, D. 
Milcic, L. Krdzalic, D. Rasic. Therapeutic 
effects of Urotovet (methenamine 
hydrothiocyanate) in controlling bacterial 
infections of the respiratory tract of 
domestic animals Terapijski efekti 
Urotoveta u saniranju bakterijskih infekcija 
respiratornog trakta domacih zivotinja. 
Veterinarski Glasnik. 1989. 43:903-908. 
 
Study in Russian 
S. Simko. Results achieved in treating the 
respiratory syndrome in calves with a feed 
mixture medicated with erythromycin 
Vysledky dosiahnute pri terapii respiracneho 
syndromu teliat medikovanym krmnym 
priprakom s erytromycinom. Veterinarstvi. 
1989. 39:164-166. 
 
Study in Serbo-Croatian 
S. Simko, L. Gestes. Epidemiological 
evaluation of the efficacy of a tylosin and 
sulfadimidine combination in the treatment 
of the respiratory syndrome in calves 
Epizootologicke zhodnotenie ucinku 
kombinacie tylozinu a sulfadimidinu pri 
terapii respiracneho syndromu teliat. 
Veterinarstvi. 1989. 39:302-304. 
 
Study in Slovakian 
F. Ascher, L. Maynard. Clinical efficacy of 
the cephalexin-colistin combination in the 
treatment of enzootic infectious 
bronchopneumonia Efficacite clinique de 
l'association cephalexin-colistine dans le 
traitement des bronchopneumonies 
infectieuses enzootiques. Maladies 
respiratoires des jeunes bovins. Paris, 24-25 
novembre 1988. 1988. Pp. 200-203. 
 
Study in French 
V. de Haas, J. L. Abric, D. B. Anderson, W. 
B. Young. A flunixin-meglumine 
oxytetracycline combination in the treatment 
of pneumonia in calves Interet de 
l'association d'un anti-inflammatoire non 
Study in French 
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steroiden (AINS), la flunixine meglumine, a 
un antibiotique dans le traitement d'une 
pneumonie chez le veau. Maladies 
respiratoires des jeunes bovins. Paris, 24-25 
novembre 1988. 1988. Pp. 219-221. 
 
C. Rindlisbacher. Treatment of bacterial 
diseases in calves by sulfonamide-
trimethoprim combinations: comparison of 
the clinical effect of two preparations 
Behandlung bakterieller Kalberkrankheiten 
mit Sulfonamid-Trimethoprim-
Kombinationen: Vergleich der klinischen 
Wirkung zweier Praparate. Schweizer Archiv 
fur Tierheilkunde. 1988. 130:51. 
 
Study in German 
S. Siebert. Comparative studies on the 
efficacy of two non-steroid anti-
inflammatory agents (acetylsalicylic acid 
and UH-AC 62-Boehringer) in combination 
with conventional antibacterial therapy in 
enzootic bronchopneumonia of cattle 
Vergleichende Untersuchungen uber die 
Wirksamkeit zweier nicht-steroidaler 
Antiphlogistika (Acetylsalicylsaure und UH-
AC 62-Boehringer) in Kombination mit der 
konventionellen antibakteriellen Therapie 
bei der Enzootischen Bronchopneumonie 
des Rindes. Vergleichende Untersuchungen 
uber die Wirksamkeit zweier nicht-
steroidaler Antiphlogistika 
(Acetylsalicylsaure und UH-AC 62-
Boehringer) in Kombination mit der 
konventionellen antibakteriellen Therapie 
bei der Enzootischen Bronchopneumonie 
des Rindes. 1988. 159 pp. 
 
Study in German 
M. Vucko, M. Potocnjak. Prevention of 
bronchopathies in beef cattle (with a long-
acting i.m. oxytetracycline preparation) 
Prilog preveniranju bronhopatija tovne 
junadi. Veterinarski Glasnik. 1988. 42:647-
651. 
 
Study in Serbo-Croatian 
R. Bauditz. Results from clinical studies 
with Baytril (Bay Vp 2674) in cattle 
Study in German 
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Ergebnisse klinischer Untersuchungen mit 
Baytril (Bay Vp 2674) bei Rindern. 
Praktische Tierarzt. 1987. 68:69-70. 
 
D. R. Gill, R. A. Smith, R. B. Hicks, R. L. 
Ball. The effect of mass medication on 
health and performance of newly arrived 
stocker cattle. Animal Science Research 
Report. Miscellaneous Publication, 
Oklahoma Agricultural Experiment Station. 
1986. 118:260-268. 
 
Not published in a journal 
R. A. Smith, R. B. Hicks, D. R. Gill, R. L. 
Ball. The response of newly arrived stocker 
cattle to different medical regimens. Animal 
Science Research Report. Miscellaneous 
Publication, Oklahoma Agricultural 
Experiment Station. 1986. 118:269-272. 
 
Not published in a journal 
E. Paiaro, A. Mencarelli. Apramaycin 
treatment to control the respiratory 
syndrome in fattening cattle of the Limousin 
breed Indagine conoscitiva sul dosaggio 
terapeutico della apramicina per il controllo 
della sindrome respiratoria in broutards di 
razza Limousin. Atti della Societa Italiana 
di Buiatria. 1986. 18:535-543. 
 
Study in Italian 
R. L. Morter, J. R. Boyce, H. E. Amstutz. 
Treatment of bovine respiratory disease with 
erythromycin and amoxicillin. Bovine 
Practitioner. 1986. 21:62-64. 
 
This was not a comparison between 
treatments. The study involved 
sequential treatment for BRD using the 
same antimicrobials in the sequence.  
R. Allaire, J. P. Raynaud, F. van Gool, J. 
Espinasse. Antibiotics with and without 
corticosteroids: assessment of different 
therapeutic strategies in the treatment of 
infectious bronchopneumonia of bacterial 
origin in young cattle Antibiotiques avec ou 
sans corticosteroides: bilan de differentes 
strategies therapeutiques dans le traitement 
des broncho-pneumonies infectieuses 
enzootiques (B.P.I.E.) d'origine bacterienne 
des jeunes bovins. Bulletin Mensuel de la 
Societe Veterinaire Pratique de France. 
1986. 70:261...279. 
Study in French 
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F. Zundel, M. Libersa, J. Lamblin, D. 
Gouffe, P. Brocvielle. Comparison of 
antibiotic with and without a non-steroidal 
anti-inflammatory in the treatment of 
respiratory diseases of young cattle 
Comparaison de deux traitements 
antibiotiques avec et sans antiinflammatoire 
non steroidien dans les pneumopathies des 
jeunes bovins. Point Veterinaire. 1986. 
18:650-653. 
 
Study in French 
R. Allaire, J. P. Raynaud, F. van Gool, J. 
Espinasse. Therapeutic strategies for 
endemic infectious bronchopneumonia of 
young cattle Bilan de differentes strategies 
therapeutiques dans les broncho pneumonies 
infectieuses enzootiques (B.P.I.E.) des 
jeunes bovins. Proceedings of the 14th 
World Congress on Diseases of Cattle, 
Dublin. 1986. 1:600-605. 
 
Study in French 
J. Espinasse, R. Allaire, J. P. Raynaud, F. 
van Gool, G. Tixier. Combination of 
glucocorticoid and antibiotic therapy for 
infectious endemic bronchopneumonia of 
young cattle Corticotherapie associee a 
l'antibiotherapie dans les 
bronchopneumonies infectieuses 
enzootiques des jeunes bovins-(BPIE)-
resultats cliniques. Proceedings of the 14th 
World Congress on Diseases of Cattle, 
Dublin. 1986. 1:611-616. 
 
Study in French 
M. Tornquist, A. Franklin. A field trial using 
a new antibacterial substance Baytril against 
respiratory diseases in calves. Proceedings 
of the 14th World Congress on Diseases of 
Cattle, Dublin. 1986. 1:621-626. 
 
Not a US or Canadian study 
J. Brugere-Picoux, J. C. Bourgoin, M. 
Turpin. Treatment of respiratory diseases of 
calves with aminosidine (paromomycin) 
Traitement des affections respiratoires du 
veau par l'aminosidine. Recueil de Medecine 
Veterinaire. 1986. 162:141-149. 
Study in French 
Totton et al./Revised Manuscript/Page 68 
 
 
P. Montlaur, C. Diaz, G. Thiriet, M. Turpin. 
Use of aminosides to treat respiratory 
infections of young cattle: a trial of 
aminosidine Utilisation des aminosides dans 
le traitement des infections respiratoires du 
jeune bovin: essais de l'aminosidine. Revue 
de Medecine Veterinaire. 1986. 137:745-
752. 
 
Study in French 
B. Larsson, C. Fossum, M. Tornquist, P. 
Matsson, S. Alenius. Evaluation of the 
prophylactic potential of an 
immunomodulator against respiratory 
disease in calves. Acta Veterinaria 
Scandinavica. 1985. 26:262-272. 
 
Not a US or Canadian study 
S. Simko. Treatment of respiratory disease 
in calves with a combination of 
chlortetracycline and bacitracin Ucinok 
kombinacie chlortetracyklinu a bacitracinu 
pri lieceni respiracneho syndromu teliat. 
Biologizace a Chemizace Zivocisne Vyroby-
Veterinaria. 1985. 21:173-182. 
 
Study in Slovakian 
R. Z. Kurbanov, M. Sh Shakurov. Gas 
exchange and acid-base equilibrium in 
calves with respiratory disease, before and 
after treatment. Fiziologiya i patologiya 
obmena veshchestv u produktivnykh 
zhivotnykh.. 1985. Pp. 11-16. 
 
Study in Russian 
A. J. Edwards. The effectiveness of 
liquamycin LA-200 oxytetracycline as a 
therapeutic treatment for respiratory disease 
in feeder cattle. Abstract. Bovine respiratory 
disease, a symposium. 1984. Page 473. 
 
Not primary research 
W. W. Bennett, G. P. Rupp. A comparison 
of differing levels of liquamycin LA-200 
oxytetracycline with other therapeutic 
regimens for the treatment of bovine 
respiratory disease. Abstract. Bovine 
respiratory disease, a symposium. 1984. Pp. 
474-475. 
 
Not published in a journal 
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A. Hojbjerg. Treatment of pneumonia in 
bought-in calves with Linco-Spectin Vet. 
soluble powder Forsog med profylaktisk 
oral behandling af pneumoni hos indkobte 
kalve med Linco-Spectin Vet. oploseligt 
pulver. Dansk Veterinartidsskrift. 1984. 
67:14-17. 
 
Study in Danish 
L. Christensen. Preliminary experiment in 
the oral, prophylactic treatment of calves 
with Rovamycin vet. for lung infections 
Preliminaert forsog med profylaktisk 
medicinering af kalve peroralt med 
Rovamycin vet. mod lungelidelser. Dansk 
Veterinartidsskrift. 1984. 67:50-53. 
 
Study in Danish 
W. Joussellin, A. Valentin-Smith. Long-
acting oxytetracycline for respiratory 
diseases of cattle, sheep and swine, and for 
preventing ovine chlamydial abortion La 
Terramycine longue action, son emploi dans 
les pneumopathies bovines, ovines et 
porcines et la prevention de la chlamydiose 
ovine. Bulletin Mensuel de la Societe 
Veterinaire Pratique de France. 1983. 
67:459...480. 
 
Study in French 
A. P. Brylin. The microflora in lungs of 
calves suffering from bronchopneumonia 
and the effect of a gentamicin aerosol. Soviet 
Agricultural Sciences. 1983. Pp. 70-73. 
 
Not a US or Canadian study 
H. J. Behrens. Ventipulmin-granulate for 
treating bovine pneumonia Ventipulmin-
Granulate bei der Behandlung der 
Rindergrippe. Tierarztliche Umschau. 1983. 
38:628, 631-632. 
 
Study in German 
K. P. Klimenkov. Efficacy of aerosols of 
antimicrobial agents against calf 
bronchopneumonia. Veterinariya, Moscow, 
USSR. 1983. 59:50-51. 
 
Study in Russian 
V. A. Lochkarev. Intravenous streptomycin 
for calf pneumonia. Veterinariya, Moscow, 
USSR. 1983. Page 53.  
Study in Russian 
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W. L. Jenkins, L. G. Friedlander. Oral 
antibacterial therapy in pre- and 
postweaning calves. Veterinary 
pharmacology and toxicology. 1983. Pp. 
141-149. 
 
Not primary research 
S. Ghergariu, B. Ingeborg, C. Draghici, O. 
Precup, P. Miskovszky, A. Enescu. Efficacy 
of Trifadoxin sulfadoxine plus trimethoprim 
against respiratory diseases in calves 
Eficacitatea produsului trifadoxin in terapia 
bolilor respiratorii la tineretul taurin. Al II-
lea simpozion al medicamentului de uz 
veterinar si al aditivilor furajeri, Bucuresti, 
1980 (Second symposium on medicaments 
for veterinary use and feed additives). 1982. 
Pp. 81-86. 
 
Study in Romanian 
B. Madsen. Treatment of respiratory 
diseases of calves with Lincocin injection 
(lincomycin) Behandling af luftvejslidelser 
hos kalve med Lincocin Vet. inj. Et 
antibiotikum der i sin virkning har mange 
faellestraek med makroliderne. Dansk 
Veterinaertidsskrift. 1982. 65:670-672. 
 
Study in Danish 
K. Sarris, J. Andreotis, S. Kyriakis, C. 
Tsaltas, A. Papatheodorou, S. Leontides. 
Treatment of pneumonia in young calves 
with oral tylosin. Deltion tes Hellenikes 
Kteniatrikes Hetaireias (Bulletin of the 
Hellenic Veterinary Medical Society). 1982. 
33:233-242. 
 
Study in Greek 
V. Gabrijolavicius. Antibiotic therapy for 
bronchitis and bronchopneumonia in cattle 
by administration into the trachea or by 
intramuscular injection. Lietuvos 
Veterinarijos Akademijos Mokslo Darbai. 
1982. 15:24-31. 
 
Study in Lithuanian 
V. Aldrovandi, F. Caleffi. First observations 
in the use of salbutamol in respiratory 
diseases of calves Prime osservazioni 
sull'uso del salbutamolo nelle malattie 
Study in Italian 
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respiratorie dei vitelli. Obiettivi e Documenti 
Veterinari. 1982. 3:55. 
W. Hofmann, W. Schulz. Prevention and 
control of infectious herd diseases in 
fattening bulls Verhutung und Bekampfung 
infektioser Bestandserkrankungen in der 
Bullenmast. Praktische Tierarzt. 1982. 
63:698...711. 
 
Study in German 
R. A. Magonigle, R. F. McManus, L. A. 
Davey, J. P. Raynaud, R. G. Breeze. 
Terramycin/LA for the control of bovine 
respiratory disease. Proceedings. XIIth 
World Congress on Diseases of Cattle, the 
Netherlands. Volume I. 1982. Pp. 99-103. 
 
Not published in a journal 
G. H. Swenson, J. Vanhemelrijck, J. Steffan. 
Parenteral therapy of respiratory disease in 
calves with lincomycin-spectinomycin 
antibiotic combination. Proceedings. XIIth 
World Congress on Diseases of Cattle, the 
Netherlands. Volume I. 1982. Pp. 104-108. 
 
Not a US or Canadian study 
G. A. Pakhomov. Immunological reactivity 
of calves undergoing treatment (with 
levamisole for acute bronchopneumonia). 
Veterinariya, Moscow, USSR. 1982. Pp. 49-
50. 
 
Study in Russian 
G. Luckinger. Prophylactic use of Tiamutin-
premix tiamulin in fattening calves. of thesis 
Der prophylaktische Einsatz von Tiamutin-
Pramix in der Kalbermast. Der 
prophylaktische Einsatz von Tiamutin-
Pramix in der Kalbermast. 1981. 2pp. 
 
Study in German 
E. Licperta, C. Statescu, P. Balaci. Mode of 
action of a new triple sulfonamide 
sulfathiazole, sulfadimidine and 
sulfacetamide Contributii la studiul actiunii 
unei trisulfamide noi. Lucrari Stiintifice, 
Institutul Agronomic "Nicolae Balcescu", C 
(Medicina Veterinara). 1981. 24:75-78. 
 
Study in Romanian 
R. Priefler. Treatment of respiratory diseases 
in calves and young cattle with a 
Study in German 
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combination of antibiotics and the 
expectorant Bisolvon (bromhexine) 
Kombinationstherapie bei 
Atemwegserkrankungen von Kalbern und 
Jungrindern. Tierarztliche Umschau. 1981. 
36:788-789. 
 
J. Meissel. Prophylactic use of a live vaccine 
and an antibiotic solution in growing calves 
Die prophylaktische Anwendung eines 
Lebendimpfstoffes und einer 
Antibiotikalosung bei Mastkalbern. Wiener 
Tierarztliche Monatsschrift. 1981. 68:388. 
 
Study in German 
E. Aznar, A. Martinez, C. Vina, G. 
Korschevenko. Treatment of chronic 
bronchopneumonia in calves by procaine 
blockade of the stellate ganglion combined 
with intramuscular streptomycin and 
penicillin Tratamiento de la 
bronconeumonia cronica del ternero con el 
bloqueo del ganglio estelar combinado con 
la estreptopenicilina. Revista de Salud 
Animal. 1980. 2:3-21. 
 
Study in Spanish 
W. Balla, A. Artmann, H. Chowaniec. 
Further results of the treatment of enzootic 
bronchopneumonia in cattle using 
Bisolvomycin and Vorenicol (bromhexine + 
oxytetracycline + oxytetracycline + 
lidocaine and oxytetracycline + 
chloramphenicol + dexamethasone 
isonicotinate) Weitere Erfahrungen beim 
Einsatz von Bisolvomycin und Vorenicol 
zur Bekampfung der enzootischen 
Bronchopneumonie des Rindes 
("Rindergrippe"). Tierarztliche Umschau. 
1980. 35:696-697. 
 
Study in German 
J. F. Anderson, C. M. Stowe, R. E. Werdin. 
A comparison of high level intratracheal 
saline lavage and conventional routes of 
antibiotic administration in the treatment of 
acute bovine bacterial pneumonia. Bovine 
Practitioner. 1979. Pp. 27-28. 
 
Not a feedlot study. Antibiotic used 
was not identified. 
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D. D. Griffin, H. E. Amstutz, R. L. Morter, 
K. S. Hendrix, R. A. Crandall. 
Oxytetracycline toxicity associated with 
bovine respiratory disease therapy. Bovine 
Practitioner. 1979. Pp. 29-32, 34-35. 
 
Study cites tables that weren't in the 
manuscript. 
P. P. Ivanov, I. V. Chuprunova. Treatment 
of bronchopneumonia in calves (tracheal 
administration of penicillin plus 
intramuscular streptomycin). Veterinariya, 
Moscow, USSR. 1979. Pp. 68-69. 
 
Study in Russian 
Z. Volner, V. Bilic, M. Zutic, B. Zoric, M. 
Slavic. Tetracycline and long-acting 
oxytetracycline in the treatment of 
bronchopneumonia in calves Tetraciklini i 
primjena oksitetraciklina produljena 
djelovanja u lijecenju bronhopneumoni je 
teladi. Veterinarski Glasnik. 1979. 33:869-
875. 
 
Study in Serbo-Croatian 
J. Jaros. Use of the erythromycin-containing 
feed mixture Vubivet ER in the prevention 
of respiratory diseases in intensive calf 
farms Pouziti medikovane krmne smesi 
Vubivet ER v prevenci respiratornich 
chorob ve VKT. Veterinarstvi. 1979. 29:22-
23. 
 
Study in Czech 
Z. Vlcek, J. Kuja. Treatment of 
gastrointestinal and respiratory diseases of 
calves with Furantyl forte (tylosin and 
furazolidone) Zkusenosti s terapii 
gastrointestinalnich a respiratornich 
onemocneni telat Furantylem forte. 
Veterinarstvi. 1979. 29:447-448. 
 
Study in Czech 
R. A. Dzhilavyan. Use of long-acting 
tetracyclines in calf bronchopneumonia 
Primenenie prolongirovannykh 
tetratsiklinovykh antibiotikov pri 
bronkhopnevmonii telyat. Byulleten 
Vsesoyuznogo Instituta Eksperimental'noi 
Veterinarii. 1978. 32:71-73. 
 
Study in Russian 
Totton et al./Revised Manuscript/Page 74 
 
G. P. Lofgreen, D. G. Addis, J. R. Dunbar, J. 
G. Clark. Time of processing calves 
subjected to marketing and shipping stress. 
Journal of Animal Science. 1978. 47:1324-
1328. 
 
All animals received the same 
antimicrobial 
W. Balla, M. Hoog. Preliminary results on 
the use of Bisolvomycin (bromhexine + 
oxytetracycline + lidocaine) and Vorenicol 
(oxytetracycline + chloramphenicol + 
dexamethasone) for the control of enzootic 
bronchopneumonia in cattle Erste 
Erfahrungen beim Einsatz von 
Bisolvomycin und Vorenicol zur 
Bekampfung der Enzootischen 
Bronchopneumonie des Rindes 
(Rindergrippe). Tierarztliche Umschau. 
1978. 33:546-547. 
 
Study in German 
C. A. Hjerpe, T. A. Routen, E. Meissonnier. 
Theoretical and practical aspects of 
sulfonamide and antibiotic treatment of 
bacterial pneumonia in fattening cattle. 
(Translation from English into French) 
Considerations theoriques et pratiques 
concernant le traitement par les sulfamides 
et les antibiotiques de la pneumonie 
bacterienne chez les bovins a l'engrais. 
Dossiers de l'Elevage. 1977. 
2,3:45...71,9...35. 
 
Study in French 
R. Dlugosz, Z. Kazmir. Oxyvet (Polfa) and 
some immunostimulants in the treatment of 
enzootic pneumonia in calves Oxyvet-Polfa 
i wybrane preparaty bodzcowe w leczeniu 
enzootycznej bronchopneumonii cielat. 
Medycyna Weterynaryjna. 1977. 33:86-88. 
 
Study in Polish 
J. Pilaszek, S. Cakala, E. Zalewska, E. 
Sommer, Z. Synowiedzki. Efficacy of 
Tylavit-Sulfa in the prevention and 
treatment of enzootic bronchopneumonia in 
calves caused by mycoplasmas Skutecznosc 
preparatu Tylavit-Sulfa w zapobieganiu i 
leczeniu enzootycznej bronchopneumonii u 
cielat, wywolanej mykoplazmami. 
Study in Polish 
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Medycyna Weterynaryjna. 1977. 33:728-
732. 
H. Kittsteiner, U. Reuss. Experiences with a 
live parainfluenza-3 vaccine in intensively 
managed cattle Erfahrungsbericht uber den 
Einsatz einor Parainfluenza-3-
Lebendvakzine in Rinderintensivhaltungen. 
Praktische Tierarzt. 1977. 58:712-714, 716, 
718. 
 
Study in German 
G. Borgne. Difficulties in preventing 
enzootic bronchopneumonia in young cattle. 
A scheme of prophylaxis Problemes poses 
par la prophylaxie des broncho-
pneumopathies infectieuses enzootiques 
chez les jeunes bovins. Essai d'un plan de 
prophylaxie. Problemes poses par la 
prophylaxie des broncho-pneumopathies 
infectieuses enzootiques chez les jeunes 
bovins. Essai d'un plan de prophylaxie. 
1977. 96 pp. 
 
Study in French 
D. W. Vaughan. Amoxicillin injectable in 
feeder cattle - a clinical field study. 
Veterinary Medicine & Small Animal 
Clinician. 1977. 72:776-779. 
 
Unclear if this study was conducted at 
a feedlot. 
I. Clara. Endotracheal inoculation in the 
treatment of bronchial and pulmonary 
diseases of cattle Attualita ed importanza 
delle inoculazioni endotracheali nella terapia 
delle forme bronchiali e polmonari dei 
bovini. Atti della Societe Italiana di 
Buiatria. 1976. 8:371-376. 
 
Study in Italian 
S. Lerman, P. Milicic. Use of Trimetosul 
(trimethoprim with a sulphonamide) in the 
treatment of calves Upotreba Trimetosula u 
lijecenju teladi. Praxis Veterinaria. 1976. 
24:41-45. 
 
Study in Serbo-Croatian 
I. Haubrich. Treatment of respiratory 
infections in fattening calves (with 
Trimetosul) Prinos lijecenju respiratornih 
infekcija tovne teladi. Praxis Veterinaria. 
1976. 24:109, 111. 
Study in Serbo-Croatian 
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M. Savic, Z. Mihajlov, D. Vulic. Use of 
"Trimetosul" (trimethoprim and 
sulfonamide) in the treatment of respiratory 
infections in fattening heifers on a farm 
Upotreba trimetosul SF 24% otopine u 
lecenju respiratornih infekcija tovne junadi 
na jednom poljoprivrednom dobru. Praxis 
Veterinaria. 1976. 24:335-338. 
 
Study in Serbo-Croatian 
Erhard Grandel, Elmar Grandel. 
Metaphylactic use of Bisolvon (bromhexine 
hydrochloride) for bronchopneumonia in 
cattle Metaphylaktischer Einsatz von 
Bisolvon bei Rindergrippe. Tierarztliche 
Umschau. 1976. 31:20, 22. 
 
Study in German 
V. I. Levchenko, G. I. Skachkov. Treatment 
of bronchopneumonia in calves (with 
reference to sensitivity testing and 
olemorfocycline). Veterinariya, Moscow. 
1976. Pp. 91-92. 
 
Study in Russian 
J. P. Raynaud, J. Y. Meaude. Treatment of 
acute bovine microbial respiratory disease 
complex with Terramycin 100 mg/ml by 
intravenous route Traitement des affections 
respiratoires aigues d'origine microbienne 
des bovins par la Terramycine (N.D.) 100 
mg/ml en Intra-Veineuse. 20th World 
Veterinary Congress. Summaries, volume 2. 
1975. Pp. 820-821. 
 
Not published in a journal 
A. Jobard, J. P. Scheid, J. A. Grandadam, J. 
M. Boisson, A. Benet. Therapeutic use of an 
erythromycin-colistin compound in calves 
Application therapeutique de l'association 
erythromycine-colistine chez le veau. 
Bulletin Mensuel de la Societe Veterinaire 
Pratique de France. 1975. 59:487-488, 490-
492, 494. 
 
Study in French 
J. P. Raynaud, J. Y. Meaude. Intravenous 
oxytetracycline for acute respiratory 
diseases of microbial origin in cattle 
Traitement des affections respiratoires 
aigues d'origine microbienne des bovins par 
Study in French 
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la Terramycine (N.D.) 100 mg/ml en intra 
veineuse. Proceedings of the 20th World 
Veterinary Congress, Thessaloniki. 1975. 
3:1881-1884. 
 
T. Seewald. Oral treatment of bacterial 
diseases in calves and young cattle with 
Vetoprim 2400 (trimethoprim, 
sulphadimidine and sulphathiazole) Ein 
Beitrag zur oralen Behandlung von 
bakteriellen Kalber- und 
Jungrinderkrankheiten mit Vetoprim 2400. 
Tierarztliche Umschau. 1975. 30:387-388, 
390. 
 
Study in German 
Z. Jeremic. Use of Gorban (sulfadoxine plus 
trimethoprim) to treat bronchopneumonia in 
calves O upotrebi Gorbana u leceenju 
bronhopneumonije junadi. Veterinarski 
Glasnik. 1975. 29:35-37. 
 
Study in Serbo-Croatian 
J. Sokol, I. Berecky, V. Rajtar, A. Michna. 
Clinico-laboratory evaluation of the efficacy 
of Trimerazin Polfa (trimethoprim and 
sulphadimidine) in the respiratory syndrome 
in calves Klinicko-laboratorne hodnotenie 
ucinnosti Trimerazinu Polfa pri 
respiratornom syndrome u teliat. 
Veterinarstvi. 1975. 25:500-501. 
 
Study in Slovakian 
P. W. Jones. Treatment of calf pneumonia 
with tylosin. Veterinary Record. 1974. 
94:200. 
 
Not a US or Canadian study 
G. T. Woods, M. E. Mansfield, G. F. 
Cmarik. Effect of certain biologic and 
antibacterial agents on development of acute 
respiratory tract disease in weaned beef 
calves. Journal of the American Veterinary 
Medical Association. 1973. 162:974-978. 
 
Interventions were first given prior to 
weaning. 
K. Kotowski. Clinical evaluation of the 
Hoechst preparation Borgal (trimethoprim 
plus sulfadoxine) in the treatment of 
enzootic bronchopneumonia in calves 
Klimiczna ocena preparatu Borgal-Hoechst 
Study in Polish 
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w leczeniu enzootycznego odoskrzelowego 
zapalenia pluc cielat. Medycyna 
Weterynaryjna. 1973. 29:93-94. 
 
V. Gabrijolavicius. Treatment of 
bronchopneumonia in cattle by tracheal 
administration of drugs (antibiotics) in 
powder form Galviju bronchopneumoniju 
gydymas, supurskiant vaistu tirpalus i 
kvepavimo takus bei plaucius. Trudy 
Litovskii Veterinarnoi Akademii. 1972. 
10:197-206. 
 
Study in Lithuanian 
T. J. Keefe, G. J. Christie, P. W. Strom. 
Clinical efficacy of ampicillin trihydrate 
veterinary injection in cattle. Veterinary 
Medicine and Small Animal Clinician. 1972. 
67:1135-1138. 
 
Study was not a clinical trial 
E. Snyder, B. Credille, R. Berghaus, S. 
Giguere. Prevalence of multi drug 
antimicrobial resistance in isolated from 
high-risk stocker cattle at arrival and two 
weeks after processing. Journal of animal 
science. 2017. 95:1124-1131. 
 
Study conducted on pastures, not 
feedlot 
C. Fennell, J. B. Gunn, G. A. M. Sharman. 
The treatment of calf pneumonia with 
etamiphylline camsylate as an adjunct to 
antibiotic therapy, compared with 
betamethasone. Veterinary Practice, UK. 
1975. 7:10-11. 
 
Not a US or Canadian study 
V. A. Fortushnyi. Aerosol therapy of calf 
pneumonia (with combinations of antibiotics 
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Table 1 
Results of a database search conducted in MEDLINE® (Web of ScienceTM) on 15 April 2017 for 
a survey of clinical trials conducted in Canada and/or the USA examining the comparative 
efficacy of at least one FDA-registered antimicrobial against naturally acquired BRD in weaned 
beef calves. Search dates were restricted to 1970 to present (2017). There were no language or 
document-type restrictions. 
Search 
no 
 
Search string # Hits
1 TS=(beef OR bovine OR calf OR calves OR cattle OR cow OR 
cows OR dairy OR Hereford OR Holstein OR ruminant OR 
ruminants OR steer OR steers) 
 
443,367
2 TS=(bovine respiratory disease OR Bovine viral diarrhea OR 
Bovine viral diarrhea virus OR undifferentiated fever OR BRD 
OR BVD OR BVDV OR Haemophilus somnus OR 
Histophilus somni OR IBR OR Infectious bovine 
rhinotracheitis OR Mannheimia hemolytica OR Pasteurella 
multocida OR Pasteurellosis OR respiratory disease OR 
undifferentiated bovine respiratory disease) 
 
198,197
3 TS=(amoxicillin OR ampicillin OR antibiotic OR antibiotics 
OR antimicrobial OR antimicrobials OR erythromycin OR 
ceftiofur OR cloxacillin OR danofloxacin OR enrofloxacin OR 
florfenicol OR gentamycin OR lincomycin OR oxytetracycline 
OR penicillin OR spectinomycin OR sulfamethoxazole OR 
tilmicosin OR trimethoprim OR tulathromycin OR tylosin OR 
gamithromycin OR danofloxacin OR tildipirosin) 
 
443,841
4 #1 AND #2 AND #3 
 
676
 
Table 2 
Reporting characteristics from a survey of clinical trials conducted in Canada and/or the USA 
examining the comparative efficacy of at least one FDA-registered antimicrobial against 
naturally acquired BRD in weaned beef calves. 
 
REFLECT reporting item 
Published 
pre-2010
Prevalence 
Published  
post-2010 
 
Prevalence 
PR1
(95% 
CI)
Item 1. In the Title and/or Abstract, did the investigators 
report that the study units were randomly allocated to the 
interventions? Yes2 
 
20/653
(31%)
 
174/28 
(61%) 
1.97
(1.23, 
3.16)
Item 2. In the Introduction, did the investigators provide 
a scientific background of the topic and a rationale 
(explanation) for the study? Yes 
 
64/675
(95.5%)
28/28 
(100%) 
1.04 
(0.96, 
1.12)
Item 3.1. In the Methods, did the investigators report 
eligibility criteria for the owner/manager/feedlot(s)? Yes 
0/67
(0%)
2/28 
(7.1%) 
 
11.7 
(0.58, 
237)
                                                 
1 Prevalence ratio (calculated as for Risk Ratio). If any cell in the 2 X 2 table had a zero value, 0.5 was added to the 
value in each cell in the 2 X 2 table prior to calculating the prevalence ratio, as per the recommendation at OpenEpi: 
http://www.openepi.com/TwobyTwo/TwobyTwo.htm. 
2 This question was scored "Yes" if the authors used any form of the term "random" including systematic 
randomization. 
3 Two references (not included in the denominator) did not have an abstract. Of the 65 papers included in the 
denominator, 14 did not mention randomizing the study units to the intervention groups anywhere in the paper, and 
they therefore may not have been randomized clinical trials. 
4 One of these studies reported in the Abstract that the study units were"systematically randomized" to the 
interventions. 
5 One of these 67 references did not have an Introduction section. 
Item 3.2. In the Methods, did the investigators report 
study unit (animal) eligibility? Yes 
42/67
(63%)
18/28 
(64%) 
 
1.03 
(0.74, 
1.43)
Item 3.3. In the Methods, was the setting where the data 
were collected described? Yes 
42/67
(63%)
26/28 
(93%) 
1.48
(1.2, 
1.83)
Item 4. In the Methods, did the investigators give precise 
details of the interventions intended for each group, the 
level at which the intervention was allocated, and how 
and when interventions were actually administered? Yes 
 
54/676
(81%)
 
26/287 
(93%) 
1.15 
(0.99, 
1.35)
Item 5.1. Did the investigators report the specific 
objectives of the study? Yes 
 
64/67
(96%)
27/28 
(96%) 
1.01 
(0.92, 
1.10)
Item 5.2. Did the investigators report the specific 
hypotheses of the study? Yes 
 
6/67
(9.0%)
9/28 
(32%) 
3.59
(1.41, 
9.13)
Item 6. Did the investigators give clearly defined primary 
and secondary outcome measures and the levels at which 
they were measured, and, when applicable, any methods 
used to enhance the quality of the measurements? Yes 
 
21/67
(31%)
10/28 
(36%) 
1.14 
(0.62, 
2.10)
Item 7. Did the investigators report how the sample size 
was determined and, when applicable, give an 
explanation of any interim analyses and stopping rules? 
Yes 
 
10/67
(15%)
5/28 
(18%) 
1.20 
(0.45, 
3.18)
Item 8. Did the investigators report the method used to 
generate the random allocation sequence at the relevant 
15/458
(33.3%)
8/219 
(38.1%) 
1.14 
(0.58, 
2.27)
                                                 
6 Route of administration of the intervention was not reported in 11 of the 67 references; dose of the intervention 
was not reported in 3 of the 67 references. 
7 Route of administration of the intervention was not reported in 2 of the 28 references. 
8 14 of the references published prior to 2010 did not mention randomization and 8 studies that mentioned that the 
study units were systematically randomized to the interventions were not included in the denominator. 
9 7 studies that reported systematic randomization were not included in the denominator. 
level of the organizational structure, including details of 
any restrictions? Yes 
 
Item 9. Did the investigators report the method used to 
implement the random allocation sequence at the 
relevant level of the organizational structure, (e.g. 
numbered containers), clarifying whether the sequence 
was concealed until interventions were assigned? Yes 
 
0/45
(0%)
0/21 
(0%) 
2.091 
(0.04, 
101.9) 
Item 10.1. Did the investigators report who generated the 
allocation sequence? Yes10 
1011/45
(22.2%)
912/21 
(42.9%) 
 
 
1.93 
(0.92, 
4.03)
Item 10.2. Did the investigators report who enrolled 
study units? Yes 
 
1/67
(1.5%)
3/28 
(11%) 
 
7.18 
(0.78, 
66.1)
Item 10.3. Did the investigators report who assigned 
study units to their groups at the relevant level of the 
organizational structure? Yes 
 
113/67
(1.5%)
0/28 
(0%) 
0.78 
(0.03, 
18.6)
Item 11.1. Did the investigators report whether or not 
those administering the interventions were blinded? Yes 
 
614/67
(9%)
715/28 
(25%) 
2.79 
(1.03, 
7.57)
                                                 
10 Denominators calculated as per item 8.  
11 For all 10 studies, a computer was used to generate the sequence. The identity of the person operating the 
computer was not reported. 
12 The random sequence was generated by a biostatistician (3 studies), the study investigator (1 study), the study 
monitor (1 study), and by a computer (computer operator not reported) (4 studies). 
13 This was done by the study investigator (1 study). 
14 In 3 of these 6 studies, the authors reported that the people giving the intervention were not blinded. The reason 
for this was not explained. 
15 In 6 of these 7 studies, the authors reported that the people giving the intervention were not blinded. For 2 of these 
6 studies, the authors explained that lack of blinding was due to the staff needing to know which drug to administer; 
for the remaining 4 studies, the authors did not give a reason for the lack of blinding. 
Item 11.2. Did the investigators report whether or not 
caregivers were blinded? Yes 
416/67
(6%)
217/28 
(7%) 
 
1.20 
(0.23, 
6.20)
Item 11.3. Did the investigators report whether or not 
those assessing the outcomes were blinded? Yes 
 
3718/67
(55%)
2419/28 
(86%) 
 
1.55 
(1.19, 
2.02)
Item 11.4. Did the investigators report whether or not 
those analyzing the data were blinded? Yes 
 
0/67
(0%)
0/28 
(0%) 
 
2.34 
(0.05, 
115)
Item 11.5. Did the investigators report blinding (or the 
absence of blinding) at all? Yes 
 
40/67
(60%)
26/28 
(93%) 
1.56 
(1.25, 
1.94)
Item 12. Were statistical methods used to compare 
groups for all BRD outcome(s) and did the investigators 
clearly state the level of statistical analysis and methods 
used to account for the organizational structure (where 
applicable)?  Yes 
 
4620/67
(69%)
 
24/28 
(86%) 
1.25 
(1.00, 
1.57)
Item 13. In the Results, did the investigators report the 
flow of study units through each stage for each level of 
the organization structure of the study? Yes 
 
45/67
(67%)
 
17/28 
(61%) 
0.90 
(0.64, 
1.27)
Item 14. Did the investigators report dates defining the 
periods of recruitment and follow-up? Yes 
 
33/67
(49%)
 
21/28 
(75%) 
1.52 
(1.10, 
2.11)
                                                 
16 For 1 of these 4 studies, the caregivers were reported to not be blinded, and a reason was given. 
17 For 1 of these 2 studies, the caregivers were not blinded. The authors did not report a reason for this. 
18 For 2 of these 37 studies, the outcome assessors were reported to not be blinded and a reason was given in each 
case. 
19 For 7 of these 24 studies, at least one of the outcome assessors was reported to be not blinded. For 3 of 7 of these 
studies, a reason was reported for the absence of blinding. 
20 For 5 studies (not included in the 46), the way the animals were housed was not described in enough detail to 
determine if clustering by pen should have been taken into account in the analysis or not. 
Item 15. Did the investigators report the baseline 
demographic and clinical characteristics of each group, 
explicitly providing information for each relevant level 
of the organizational structure? Yes 
 
27/67
(40%)
 
15/28 
(55%) 
1.33 
(0.85, 
2.09)
Item 16. Did the investigators report the number of study 
units (denominator) in each group included in each 
analysis and the results in absolute numbers when 
feasible? Yes 
 
43/67
(64%)
 
18/28 
(64%) 
1.00 
(0.72, 
1.39)
Item 17. Did the investigators, for the BRD outcome(s) 
only, report a summary of results for each group, 
accounting for each relevant level of the organizational 
structure, and the estimated effect size and its precision 
(e.g., 95% confidence interval)? Yes 
 
15/67
(22%)
 
7/28 
(25%) 
1.12 
(0.51, 
2.44)
Item 18. Did the investigators address multiplicity by 
reporting any other analyses performed, including 
subgroup analyses and adjusted analyses, indicating 
those pre-specified and those exploratory? Yes21 
 
322/34
(8.8%)
0/7 
(0%) 
0.63
(0.04, 
10.93)
Item 19. Did the investigators report all important 
adverse events or side effects in each intervention group? 
Yes 
 
11/67
(16%)
 
4/28 
(14%) 
0.87
(0.30, 
2.50)
 
 
                                                 
21 The denominators comprise only those studies with 3 or more arms. A study was scored Yes if Tukey's test, 
Ducan's multiple range test, Fisher's LSD, or the Bonferroni method were reported with respect to BRD outcomes 
only. 
22 All 3 studies reported using Duncan's multiple range test. 
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